*Ganesh A. Thakur; May 7, 2024*

# CURRICULUM VITAE

**NAME**: Ganesh A. Thakur, Ph.D.

**OFFICE ADDRESS:** Department of Pharmaceutical Sciences, 140 The Fenway, Room # 145,
Northeastern University, Boston, MA 02115
Telephone: 617-373-8163 (Office),
860-983-1021 (cell)
Fax: 617-373-8886;
E-Mail: g.thakur@northeastern.edu

**CITIZENSHIP:** U.S. Citizen

## I . EDUCATION AND EMPLOYMENT HISTORY:

### 1. EDUCATION

| Year | Degree | Institution |
|---|---|---|
| 1990-1993 | B.S. (Chemistry) | University of Mumbai, India |
| 1993-1995 | M.S. (Chemistry) | Indian Institute of Technology (IIT), Mumbai, India |
| 1995-2000 | Ph.D. (Organic Chemistry) | Institute of Chemical Technology (ICT), Mumbai, India. |

### 2. POSTDOCTORAL TRAINING

07/2000- 08/2003 Postdoctoral Fellow, Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT.

### 3. ACADEMIC APPOINTMENTS

09/2003-10/2004 Assistant Research Professor, Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT.

11/2004-06/2005 Senior Research Scientist, Center for Drug Discovery, NEU, Boston, MA, USA

07/2005- 08/2010 Assistant Research Professor, Center for Drug Discovery, NEU, Boston, MA, USA.

09/2010- 08/2016 Assistant Professor (Tenure-track), Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.

09/2016 – 06/2021 Associate Professor (Tenured), Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.

07/2017-06/2018 Vice Chair, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA.

07/2021- current Professor, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, USA.

07/2018- 06/2020 Interim Chair, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA.

07/2020- current Chairman, Department of Pharmaceutical Science, Northeastern University, Boston, MA.

### 4. AWARDS AND HONORS

1995 Recipient of Fellowship of University Grant Commission (UGC, India) as a Junior Research Fellow

1998 Recipient of Fellowship of University Grant Commission (UGC, India) as a Senior Research Fellow

1998 Recipient of "Best Paper Presentation Award" in XIV$^{th}$ Carbohydrate Conference Conducted by Indian Institute of Technology (IIT) in collaboration with Association of Carbohydrate Chemists & Technologists, India.

2009 Early Career Development Award in Chemistry of Drug Abuse and Addiction (ECHEM) from NIDA.

2011 Excellence in Teaching Award, School of Pharmacy, Northeastern University, Boston, MA 02115

2014 The Schumacher Award for Excellence in Research, Northeastern University, Boston, MA 02115

2015 RISE (Research, Innovation, Scholarship, and Expo) Award in Health Sciences, NEU, Boston, 2015 (Graduate Student: Abhijit Kulkarni)

2015 Nominated for Northeastern University's University-wide "Excellence in Teaching Award."

2015 Nominated for "Bouve College Distinguished Educator Award" for the year 2015.

2015 Guest Speaker, Rho Chi Society's Annual Lecture Series, 2015.

2018 Best Patent Award from the Boston Patent Law Association (BPLA). Patent Title: Allosteric Modulators of CB1 Cannabinoid Receptor. *United States Patent #9,926,275 B2

2019 Excellence in Teaching Award, School of Pharmacy, Northeastern University, Boston, MA 02115

2022 RISE (Research, Innovation, Scholarship, and Expo) Award in Health Sciences, NEU, Boston, MA 02115 (Graduate Student: Lucas Cantwell)

2023 Hind Rattan Award, Given by the NRI Welfare Society of India

2023 Distinguished Mentor Award, Bouve College of Health Sciences, Northeastern University, Boston, MA.

**5. <u>IN NEWS/MEDIA:</u>**

1) "Last Dance with Mary Jane" http://www.northeastern.edu/news/2014/03/thakur/
2) "A Promising Alternative to Medical Marijuana: http://www.northeastern.edu/news/2014/09/promising-alternative-medical-marijuana/
3) "Smarten Up" http://www.northeastern.edu/news/2014/03/smarten-up/
4) "Local researchers work to eliminate high from medical marijuana" http://boston.cbslocal.com/tag/ganesh-thakur/
5) "Hope the prescription can mimic marijuana's benefits" https://www.bostonglobe.com/lifestyle/health-wellness/2014/11/17/some-parents-children-who-have-seizures-are-hoping-that-prescription-drug-will-able-mimic-marijuana-benefits/KoGizuhG99EO3w0RkyOrcO/story.html
6) Discovering drug treatments for alcohol addiction (Project with an undergraduate student) https://news.northeastern.edu/2017/04/discovering-drug-treatments-for-alcohol-addiction/
7) Novel Compound Alleviates Hard-to-Treat Pain in Mice (NIH Highlight) https://www.drugabuse.gov/news-events/nida-notes/2018/06/novel-compound-alleviates-hard-to-treat-pain-in-mice

8) "The drug could stop the opioid epidemic"
https://news.northeastern.edu/2018/12/05/this-drug-could-stop-the-opioid-epidemic/

## II. RESEARCH AND SCHOLARSHIP:

**GOOGLE SCHOLR ANALYSIS:** (as of 10/10/2023)**: H-index = 41**; **i10-index = 94**; Total Citations = **4690;**

Total publications = **115**; Manuscripts under review = **1**; Book Chapters = **4**; Total patents = **8**.

### A. PEER-REVIEWED PUBLICATIONS (IN CHRONOLOGICAL ORDER)

1. Rao, P. S., **Thakur, G.A.**, Lahiri, G. K., Synthesis, characterization and redox properties of ruthenium (II) phenolato Schiff base mixed ligand complexes. *Indian Journal of Chemistry, Sect. A: Inorganic, Bio-inorganic, Physical, Theoretical and Analytical Chemistry*, **1996**, 35A (11), 946-951.

2. Santra, B. K., **Thakur G. A.**, Ghosh, P., Pramanik, A., Lahiri, G. K., A novel example of metal-mediated aromatic thiolation in ruthenium complex: crystal structure of RuII (SC6H4N:NC5H4N)2. *Inorganic Chemistry*, **1996**, 35(10), 3050-3052.

3. **Thakur, G. A.**, Narayanswami, K., Lahiri, G. K., Synthesis, characterization and redox properties of ruthenium (II) dithiocarbonato complexes having 2,2'-bipyridine co-ligands. *Indian Journal of Chemistry, Section A: Inorganic, Bio-inorganic, Physical, Theoretical and Analytical Chemistry*, **1996**, 35A (5), 379-384.

4. Nikas, S. P., **Thakur, G. A.**, Makriyannis, A., A convenient and effective synthesis of 3-(3,5-Dimethoxyphenyl)propanal. *Synthetic Communications*, **2002**, 32(11), 1751-1756.

5. Palmer, S., **Thakur, G. A.**, Makriyannis, A., Cannabinergic ligands. *Chemistry and Physics of Lipids*, **2002**, 121(1-2), 3-19.

6. Nikas, S. P., **Thakur, G. A.**, Makriyannis, A., Synthesis of side chain specifically deuterated(-)-$\Delta^9$-tetrahydrocannabinoids. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2002**, 45, 1-12.

7. Nikas, S. P., **Thakur, G. A.**, Makriyannis, A., Regiospecifically deuterated (-)-$\Delta^9$-tetrahydrocannabivarins. *J. Chem. Soc. Perkin. Trans.*1, **2002**, 22, 2544-2548.

8. **Thakur, G. A.,** Palmer, S., Harrington, P. E., Stergiades, I. A., Tius, M. A., Makriyannis, A., Enantiomeric resolution of a novel chiral cannabinoid receptor ligand. *Journal of Biochemical and Biophysical Methods*, **2002**, 54(1-3), 415-422.

9. Lu, D., Meng, Z., **Thakur, G. A.**, Fan, P., Steed, J., Tartal, C. L., Hurst, D. P., Reggio, P. H., Deschamps, J. R., Parrish, D. A., George, C., Jarbe, T. U., Lamb, R. J., Makriyannis, A., Adamantyl Cannabinoids: A novel class of cannabinergic ligands. *Journal of Medicinal Chemistry*, **2005**, 48 (14), 4576-4585.

10. McLaughlin, P. J., Lu, D., Winston, K. M., **Thakur, G. A.**, Swezey, L. A., Makriyannis, A., Salamone, J. D., Behavioral effects of the novel cannabinoid CB1 agonist AM411. *Pharmacology Biochemistry and Behavior*, **2005**, 81(1), 78-88.

11. McLaughlin, P. J., Brown, C. M., Winston, K. M., **Thakur, G. A.**, Lu, D., Makriyannis, A., Salamone, J. D., The novel cannabinoid agonist AM 411 produces a biphasic effect on accuracy in a visual target detection task in rats. *Behavioral Pharmacology*, **2005**, 16(5-6), 477-486.

12. Picone, R. P., Khanolkar, A. D., Xu, W., Ayotte L. A., **Thakur, G. A.**, Hurst, D. P., Abood, M. E., Reggio, P. H., Fourier, D. J., Makriyannis, A., (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. *Molecular Pharmacology*, **2005**, 68 (6), 1623-1635.

13. **Thakur, G. A.**, Nikas, S. P., Makriyannis, A., CB1 Cannabinoid receptor ligands. *Mini Reviews in Medicinal Chemistry*, **2005**, 5(7), 631-640.

14. **Thakur, G. A.**, Duclos, R.I., Jr., Makriyannis, A., Natural cannabinoids: templates for drug discovery. *Life Sciences*, **2005**, 78(5), 454-466.

15. Pavlopoulos, S., **Thakur, G. A.**, Nikas, S. P., Makriyannis, A., Cannabinoid receptors as therapeutic targets. *Curr. Pharm. Design*, **2006**, 12(14), 1751-1769.

16. Kapur, A., Hurst, D. P., Fleischer, D., Whitnell, R., **Thakur, G. A.**, Makriyannis, A., Reggio, P. H., Abood, M. E., Mutation studies of Ser7.39 and Ser2.60 in the human $CB_1$ cannabinoid receptor: evidence for a serine induced bend in $CB_1$ transmembrane helix 7. *Molecular Pharmacology*, **2007**, 71(6), 1512-1524.

17. Nikas, S. P., **Thakur, G. A.**, Parrish, D. A., Alapafuja, S. O., Huestis, M., Makriyannis, A., A concise methodology for the synthesis of (−)-$\Delta^9$-tetrahydrocannabinol and (−)-$\Delta^9$-tetrahydrocannabivarin metabolites and their regiospecifically deuterated analogs. *Tetrahedron*, **2007**, 63, 8112-8123.

18. Khanolkar, A. D., Lu, D., Ibrahim, M., Duclos, R.I. Jr., **Thakur, G. A.**, Malan, T. P. Jr., Porreca, F., Veerappan, V., Tian, X., George, C., Parrish, D. A., Papahatjis, D. P., Makriyannis, A., Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. *Journal of Medicinal Chemistry*, **2007**, 50 (26), 6493-6500.

19. Sink, K.S., McLaughlin, P.J., Wood, J.A., Brown, C., Fan, P., Vemuri, V.K., Peng, Y., Olzewska, T., **Thakur, G.A.**, Makriyannis, A., Parker, L.A., Salamone, J.D., The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. *Neuropsychopharmacology*, **2008**, 33(4), 946-955.

20. Kapur, A., Samaniego, P., **Thakur, G. A.**, Makriyannis, A., Abood, M. E., Mapping the structural requirements in the CB1 cannabinoid receptor transmembrane helix II for signal transduction. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 325 (1), 341-348.

21. Bergman, J., Delatte, M. S., Paronis, C. A., Vemuri, V. K., **Thakur, G. A.**, Makriyannis, A., Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. *Physiology & Behavior*, **2008**, 93(4-5), 666-670.

22. Rahn, E. J., Zvonok, A. M., **Thakur, G. A.**, Khanolkar, A. D., Makriyannis, A., Hohmann, A. G., Selective activation of cannabinoid $CB_2$ receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 327(2), 584-591.

23. Pei, Y., Mercier, R. W., Anday, J. K., **Thakur, G. A.**, Zvonok, A. M., Reggio, P. H., Janero, D. R., Makriyannis, A., Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for a receptor subtype-specific binding motif and modeling GPCR activation. *Chemistry & Biology*, **2008**, 15(11), 1207-1219.

24. Sink K. S., Segovia K. N., Nunes E. J., Collins L. E., Vemuri V. K., **Thakur G. A.**, Makriyannis A., Salamone J. D. Intracerebroventricular administration of cannabinoid CB1 receptor antagonists AM251 and AM4113 fails to alter food-reinforced behavior in rats. *Psychopharmacology* (Berl.), **2009**, 206(2), 223-232.

25. **Thakur GA***, Tichkule, R., Bajaj, S., Makriyannis, A. R Recent advances in cannabinoid receptor agonist. *Expert Opinion on Therapeutic Patents*. **2009**, 19 (12), 1647-73.

26. Dixon, D. D., Sethumadhavan, D., Benneche, T., Banaag, A. R., Tius, M. A., **Thakur, G. A.**, Bowman, A., Wood, J., Makriyannis, A. Heteroadamantyl Cannabinoids. *Journal of Medicinal Chemistry,* **2010**, 53(15), 5656-66.

27. Rahn, E., **Thakur, G. A.**, Zvonok, A. M., Vemuri, V. K., Makriaynnis, A., Hohmann, A. G., Pharmacological characterization of putative cannabinoid CB2 agonist from the cannabilactone class: Antinociception without central nervous system side-effects. *Pharmacology, Biochemistry & Behavior*, **2011**, 98, 493-502.

28. Teng, H.[1], **Thakur, G. A.[1]**, Makriyanis, A. Conformationally restricted analogs of BAY59-3074 as novel cannabinoid receptor ligands. *Bioorganic & Medicinal Chemistry Letters*, **2011**, 21, 5999-6002. (**[1]** Equal author contribution)

29. Szymanski,D. W., Papanastasiou, M., Melchior, K., Zvonok, N., Mercier, R. W., Janero, D. R., **Thakur, G. A.**, Cha, S., Wu, B., Karger, B., Makriyannis, A. Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation, *Journal of Proteome Research,* **2011**, 10, 4789-4798.

30. Wilkerson, J.L., Gentry, K.R., Dengler, E.C., Wallace, J.A., Kerwin, A.A., Kuhn, M.N., Zvonok, A.M., **Thakur, G.A.,** Makriyannis, A., Milligan, E.D. Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia. *Brain and Behavior*, **2012**, 2(2), 155-177.

31. Wilkerson, J.L., Gentry, K.R., Dengler, E.C., Wallace, J.A., Kerwin, A.A., Armijo, L.M., Kuhn, M.N., **Thakur, G.A.,** Makriyannis, A., Milligan, E.D., Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels. *Pain*, **2012**, 153(5), 1091-1106.

32. Dixon, D.D., Tius, M.A., **Thakur,** G.A., Zhou, H., Bowman, A.L., Shukla, V.G., Peng, Y., Makriyannis, A. C3-Heteroaroyl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptor. *Bioorganic & Medicinal Chemistry Letters*, **2012**, 22(16), 5322-5325.

33. Deng, L., Guindon, J., Vemuri, K.V., **Thakur, G.A.**, White, F.A., Makriyannis, A., Hohmann, A.The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy. *Molecular Pain*, **2012**, 8: 71.

34. Desai, R.V., **Thakur, G.A.**, Vemuri, K.V., Bajaj, S.B., Makriyannis, A., Bergman, A. Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonists, antagonists, and non-cannabinoid drugs. *Journal of Pharmacology and Experimental Therapeutics*, **2013**, *344*, 319-328.

35. Paronis, C.A., **Thakur, G.A.**, Bajaj, S.B., Nikas, S.P., Vemuri, K.V., Makriyannis, A., Bergman, J. Diuretic Effects of Cannabinoids. *Journal of Pharmacology and Experimental Therapeutics*, **2013**, *314*, 8-14.

36. **Thakur, G.A.*,** Bajaj, S.B., Paronis, C.A., Peng, Y., Bowman, A.L. Barak, L., Caron, M.G. Parrish, D.A., Deschamps, J., Makriyannis, A. Novel Adamantyl Cannabinoids as CB1 Receptor Probes, *Journal of Medicinal Chemistry,* **2013**, 6(10):3904-3921.

37. McLaughlin, P.J., **Thakur, G. A.**, McClure, E.D., Brown, C.M., Winston, K.M., Wood, J.T., Makriyannis, A., Salamone, J.D. Behavioral effects of the novel potent cannabinoid CB1 agonist AM4054, *Pharmacology Biochemistry and Behavior*. **2013**, 119:16-22.

38. Miller R.L., **Thakur G. A.**, Stewart W.N., Bow J.P., Bajaj S., Makriyannis A., McLaughlin P.J. Effects of a novel CB1 agonist on visual attention in male rats: role of strategy and expectancy in task accuracy. *Experimental & Clinical Psychopharmacology* **2013**; 21(5):416-25.

39. Kangas BD, Delatte M.S., Vemuri V.K., **Thakur G.A.**, Nikas SP, Subramanian KV, Shukla VG, Makriyannis A, Bergman J. Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists. *Exp Clin Psychopharmacology,* **2013**, 344(3):561-567.

40. Chopda, G. R., Vemuri, V. K., Sharma, R., **Thakur, G.A.,** Makriyannis, A., Paronis, C.A. Diuretic effects of cannabinoid agonists in mice. *European Journal of Pharmacology,* **2013**; 721(1-3):64-69

41. Kulkarni AR, **Thakur G.A.***. Microwave-assisted Expeditious and Efficient Synthesis of Cyclopentene Ring-fused Tetrahydroquinoline Derivatives Using Three-component Povarov Reaction. *Tetrahedron Letters*, **2013**, 54(48), 6592-6595.

42. Papke RL, Horenstein NA, Kulkarni AR, Stokes C, Corrie LW, Maeng CY, **Thakur G.A.***. The activity of GAT107, an allosteric activator and positive modulator of α7 nAChR, is regulated by aromatic amino acids that span the subunit interface. *Journal of Biological Chemistry,* **2014**, 289(7), 4515-4517.

43. **Thakur G.A.***, Kulkarni AR, Deschamps JR, Papke RL. Expeditious Synthesis, Enantiomeric Resolution, and Enantiomer Functional Characterization of (4-(4-Bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide (4BP-TQS): An Allosteric Agonist-Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptors. *J. Med. Chem.* **2013**; 56(21):8943-8947.

44. Sharma R, Nikas SP, Paronis CA, Wood JT, Halikhedkar A, Guo JJ, **Thakur G.A.**, Kulkarni S, Benchama O, Raghav JG, Gifford RS, Järbe TU, Bergman J, Makriyannis A. Controlled-detoxification Cannabinergic Ligands. *Journal of Medicinal Chemistry,* **2013**, 56(24):10142-10157.

45. Gamage, T., Ignatowska-Jankowska, B. M., Abdelrahman, M., Trembleau. L., **Thakur, G. A.,** Tichkule, R. B. ; Poklis, J. ; Ross, R. A., Pertwee, R. G. and Lichtman, A. H. Investigation of the *in vivo* pharmacological effects of the CB1 receptor allosteric modulator Org-27569. *Behavioral Pharmacology*, **2014** Apr; 25(2):182-185.

46. Rahn, E.J., Deng, L., **Thakur, G.A.,** Vemuri, V.K., Zvonok, A. M., Lai, Y. Y. Makriyannis, A. and Hohmann, A.G. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery *Molecular Pain*. **2014**, 10(1):27; doi:10.1186/1744-8069-10-27.

47. Fichna, J., Bawa, M., **Thakur, G.A.**, Tichkule, R., Makriyannis, A., McCafferty, D.M., Sharkey, K.A., Storr, M. Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors. *PLoS One*. **2014** Oct 2;9(10): e109115.

48. Nikas, S.P., Sharma R., Paronis, C.A., Kulkarni, S., **Thakur G.A.**, Hurst, D., Wood, J.T., Gifford, R.S., Rajarshi, G., Liu, Y., Raghav, J.G., Guo, J.J., Järbe, T.U., Reggio, P.H., Bergman, J., Makriyannis, A. Probing the Carboxyester Side Chain in Controlled Deactivation (-)-$\Delta^8$-Tetrahydrocannabinols. *Journal of Medicinal Chemistry.* **2015,** 58(2), 665-681.

49. Keenan, C.M, Storr, M.A., **Thakur, G.A.,** Wood, J.T., Wager-Miller J., Straiker, A., Eno, M.R., Nikas S.P., Bashashati, M., Hu, H., Mackie, K., Makriyannis, A. and Sharkey, K.A. AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally-restricted manner. *British Journal of Pharmacology,* **2015**, 172(9), 2406-2418.

50. Lee, W.H.; Xu, Z.; Ashpole, N.; Hudmon, A.; Kulkarni, P.M.; **Thakur, G.A.**; Lai, Y.; Hohmann, A.H. Small molecule inhibitors of protein-protein interaction as novel analgesics; *Neuropharmacology,* **2015**; 97:464-475.

51. Abalo, R.; Chen, C.; Vera, G.; Fichna, J.; **Thakur, G. A**.; López-Pérez, A. E., Makriyannis, A.; Martín-Fontelles, M. I.; Storr, M. In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat. *Neurogastroenterology and Motility,* **2015**, 27(12), 1721-1735.

52. Papke R.L., Bagdas, D., Kulkarni, A.R., Gould, T., AlSharari, S.D., **Thakur, G. A.**, Damaj, M. I. The analgesic-like properties of the alpha7 nAChR silent agonist NS6740 is associated with non-conducting conformations of the receptor. *Neuropharmacology*, **2015**; 91:34-42.

53. Kulkarni, P.M., Kulkarni, A.R., Korde A., Tichkule, R.B., Laprairie R.B., Denovan-Wright E.M., Zhou H., Janero D.R., Zvonok N., Makriyannis A., Cascio M.G., Pertwee R.G., **Thakur G.A.***. Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). *Journal of Medicinal Chemistry*, **2016** ;59(1):44-60.
***This manuscript was highlighted as the Editor's choice article.**

54. Horenstein, N.A., Papke, R.L., Kulkarni, A.R., Chaturbhuj, G.U., Stokes, C., Manther, K., **Thakur GA*.** Critical Molecular Determinants of α7 Nicotinic Acetylcholine Receptor Allosteric Activation: Separation of Direct Allosteric Activation and Positive Allosteric Modulation. *Journal of Biological Chemistry*, **2016** Mar 4;291(10):5049-5067.

55. Laprairie, R.B., Kulkarni, A.R., Kulkarni, P.M., Hurst, D.P., Lynch, D., Reggio, P.H., Janero, D.R., Pertwee, R.G., Stevenson, L.A., Kelly, M.E., Denovan-Wright, E.M., **Thakur, G.A.*.** Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe. *ACS Chemical Neuroscience*, **2016**;7(6):776-798.

56. Smith, A.E., Xu, Z., Lai, Y.Y., Kulkarni, P.M., **Thakur G.A.**, Hohmann A.G., Crystal J.D. Source memory in rats is impaired by an NMDA receptor antagonist but not by PSD95-nNOS protein-protein interaction inhibitors. *Behavioral Brain Research,* **2016**; 305:23-29.

57. Chopda, G.R., Parge, V., **Thakur, G.A.**, Gatley, S.J., Makriyannis, A., Paronis, C.A. Tolerance to the Diuretic Effects of Cannabinoids and Cross-Tolerance to κ-Opioid Agonist in THC-Treated Mice. *Journal of Pharmacology and Experimental Therapeutics.* **2016**; 358(2):334-341.

58. Bagdas D.*, Wilkerson J.L., Kulkarni A., Toma W., AlSharari S., Gul Z., Lichtman A.H., Papke R.L., **Thakur G.A.*,** Damaj M.I. The α7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain. *British Journal of Pharmacology*, **2016,**173(16):2506-2520.

59. Järbe, T.U., LeMay, B.J., **Thakur, G.A.**, Makriyannis, A. A high efficacy cannabinergics ligand (AM4054) used as a discriminative stimulus: Generalization to other adamantyl analogs and $\Delta^9$-THC in rats. *Pharmacology Biochemistry and Behavior*, **2016**; 148:46-52.

60. Janero D.R., **Thakur G.A.***. Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target. *Expert Opinion on Drug Discovery*, **2016**;11(12):1223-1237.

61. Kulkarni A.R., Garai S., **Thakur G.A.*.** Scalable, One-Pot, Microwave-Accelerated Tandem Synthesis of Unsymmetrical Urea Derivatives. *Journal of Organic Chemistry*, **2017**; 82(2):992-999.

62. Laprairie R.B., Kulkarni P.M., Deschamps J.R., Kelly M.E.M., Janero D.R., Cascio M.G., Stevenson L.A., Pertwee R.G., Kenakin T.P., Denovan-Wright E.M., **Thakur GA*.** Enantiospecific Allosteric Modulation of Cannabinoid 1 Receptor. *ACS Chemical Neuroscience*, **2017,** 8(6):1188-1203.

63. Zhou, H., Peng, Y., Halikhedkar, A., Fan, P., Janero, D.R., **Thakur, G.A.**, Mercier, R.W., Sun, X., Ma, X., Makriyannis. A. Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose. *ACS Chemical Neuroscience*, **2017**; 8(6):1338-1347.

64. Carey L.M., Lee W.H., Gutierrez T., Kulkarni P.M., **Thakur G.A.**, Lai Y.Y., Hohmann A.G. Small molecule inhibitors of PSD95-nNOS protein-protein interactions suppress formalin-evoked Fos protein expression and nociceptive behavior in rats. *Neuroscience*. **2017**; 349:303-317.

65. Papke R.L., Stokes C., Damaj M.I., **Thakur G.A.**, Manther K., Treinin M., Bagdas D., Kulkarni A.R., Horenstein N.A. Persistent activation of α7 nicotinic ACh receptors associated with stable induction of different desensitized states. *Br. J. Pharmacol.* **2017** May 6. doi: 10.1111/bph.1385.

66. Donvito G., Bagdas D., Toma W., Rahimpour E., Jackson A., Meade J.A., AlSharari S., Kulkarni A.R., Ivy Carroll F., Lichtman A.H., Papke R.L., **Thakur G.A.**, Imad Damaj M. The interaction between α7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α represents a new antinociceptive signaling pathway in mice. *Experimental Neurology*, **2017**; 295:194-201.

67. Cairns, E.A., Szczesniak, A.M., Straiker, A.J., Kulkarni, P.M., Pertwee, R.G., **Thakur, G.A.**, Baldridge, W.H., Kelly, M.E.M. The In Vivo Effects of the CB1-Positive Allosteric Modulator GAT229 on Intraocular Pressure in Ocular Normotensive and Hypertensive Mice. *Journal of Ocular Pharmacology and Therapeutics*, **2017**, 33(8):582-590.

68. Kulkarni, P.M., Ranade, A., Garai, S., **Thakur, G.A.*** Microwave-accelerated Conjugate Addition of 2-Arylindoles to Substituted β-Nitrostyrenes in the Presence of Ammonium Trifluoroacetate: An Efficient Approach for the Synthesis of a Novel Class of CB1 Cannabinoid Receptor Allosteric Modulators, **2017**, 54, 2079-2084.

69. Slivicki RA, Xu Z, Kulkarni PM, Pertwee RG, Mackie K, **Thakur GA**, Hohmann AG. Positive Allosteric Modulation of Cannabinoid Receptor Type 1 Suppresses Pathological Pain Without Producing Tolerance or Dependence. *Biological Psychiatry*. **2018**, 84(10):722-733.

70. Mitjavila J., Yin D., Kulkarni P.M., Zanato C., **Thakur G.A.**, Ross R., Greig I., Mackie K., Straiker A. Enantiomer-specific positive allosteric modulation of CB1 signaling in autaptic hippocampal neurons. *Pharmacolical Research,* **2018,** 129:475-481.

71. Shekhar, A., **Thakur, G.A**. Cannabinoid Receptor 1 Positive Allosteric Modulators for Posttraumatic Stress Disorder. *Neuropsychopharmacology*. **2018**, 43(1):226-227.

72. Ha, J., Xu Y., Kawano, T., Hendon, T., Baki, L., Garai, S., Papapetropoulos, A., **Thakur, G.A.**, Plant, L.D., Logothetis, D.E. Hydrogen sulfide inhibits Kir2 and Kir3 channels by decreasing sensitivity to the phospholipid phosphatidylinositol 4,5-bisphosphate (PIP2). *Journal of Biological Chemistry,* **2018**, 293(10):3546-3561.

73. Li, L.P., Dustrude, E.T., Haulcomb, M.M., Abreu, A.R., Fitz, S.D., Johnson, P.L., **Thakur, G.A.**, Molosh, A.I., Lai, Y., Shekhar, A. PSD95 and nNOS interaction as a novel molecular target to modulate conditioned fear: relevance to PTSD. *Translational Psychiatry*, **2018**, 8(1):155.

74. Salaga M., Binienda A., Tichkule R.B., **Thakur G.A.**, Makriyannis A., Storr M., Fichna J. The novel peripherally active cannabinoid type 1 and serotonin type 3 receptor agonist AM9405 inhibits gastrointestinal motility and reduces abdominal pain in mouse models mimicking irritable bowel syndrome. *European Journal of Pharmacology,* **2018** Oct 5; 836:34-43.

75. Garai, S., Raja, K.S., Papke, R.L., Deschamps, J.R., Damaj, M.I., **Thakur, G.A.*** B-973, a Novel α7 nAChR Ago-PAM: Racemic and Asymmetric Synthesis, Electrophysiological Studies, and *in Vivo* Evaluation. *ACS Medicinal Chemistry Letters,* **2018** Oct 11;9(11):1144-1148.

76. Quadri M., Garai S., **Thakur G.A.**, Stokes C., Gulsevin A., Horenstein N.A., Papke R.L. Macroscopic and Microscopic Activation of *α*7 Nicotinic Acetylcholine Receptors by the Structurally Unrelated Allosteric Agonist-Positive Allosteric Modulators (ago-PAMs) B-973B and GAT107. *Molecular Pharmacology.* **2019**, 95(1):43-61.

77. Pan, J., Mendes, L.P., Yao M., Filipczak, N., Garai, S., **Thakur, G.A.**, Sarisozen, C., Torchilin, V.P. Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 136:18-28.

78. Laprairie, R.B., Bagher, A.M., Rourke, J.L., Zrein, A., Cairns, E.A., Kelly, M.E.M, Sinal, C.J., Kulkarni, P.M., **Thakur G.A.**, Denovan-Wright, E.M. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model. *Neuropharmacology*. **2019**, 151:1-12.

79. Gulsevin, A., Papke, R.L., Stokes, C., Garai, S., **Thakur, G.A.**, Quadri M., Horenstein, N.A. Allosteric Agonism of α7 Nicotinic Acetylcholine Receptors: Receptor Modulation Outside the Orthosteric Site. *Molecular Pharmacology* **2019**, 95(6):606-614.

80. Stokes, C., Garai, S., Kulkarni, A.R., Cantwell, L.N., Noviello, C.M., Hibbs, R.E., Horenstein, N.A., Abboud, K.A., **Thakur, G.A.**, Papke, R.L. Heteromeric Neuronal Nicotinic Acetylcholine Receptors

with Mutant β Subunits Acquire Sensitivity to α7-Selective Positive Allosteric Modulators. *Journal of Pharmacology and Experimental Therapetuics.* **2019** Aug; 370(2):252-268.

81. Toma, W., Kyte, S.L., Bagdas, D., Jackson, A., Meade, J.A., Rahman, F., Chen, Z.J., Del Fabbro, E., Cantwell, L., Kulkarni A., **Thakur G.A.**, Papke R.L., Bigbee J.W., Gewirtz D.A., Damaj M.I. The α7 nicotinic receptor silent agonist R-47 prevents and reverses paclitaxel-induced peripheral neuropathy in mice without tolerance or altering nicotine reward and withdrawal. *Experimental Neurology,* **2019** Oct; 320:113010.

82. Hurst, D.P., Garai, S., Kulkarni, P.M., Schaffer, P.C., Reggio, P.H., **Thakur, G.A.***. Identification of CB1 Receptor Allosteric Sites Using Force-Biased MMC Simulated Annealing and Validation by Structure-Activity Relationship Studies. *ACS Medicinal Chemistry Letters,* **2019**, 10(8):1216-1221.

83. Laprairie R.B., Mohamed K.A., Zagzoog A, Kelly M.E.M., Stevenson L.A., Pertwee R., Denovan-Wright E.M., **Thakur G.A.***. Indomethacin Enhances Type 1 Cannabinoid Receptor Signaling. *Frontiers in Molecular Neuroscience,* **2019** Oct 18; 12:257.

84. Garai S., Kulkarni P.M., Schaffer P.C., Leo L.M., Brandt A.L., Zagzoog A., Black T., Lin X., Hurst D.P., Janero D.R., Abood M.E., Zimmowitch A., Straiker A., Pertwee R.G., Kelly M.E.M., Szczesniak A.M., Denovan, E.M., Mackie K., Hohmann A.G., Reggio P.H., Laprairie R.B., **Thakur G.A.*** Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators. *Journal of Medicinal Chemistry,* **2020**, 63(2), 542-568.

85. Thapa, D., Cairns, E.A., Szczesniak, A.M., Kulkarni, P.M., Straiker, A.J., **Thakur, G.A.**, Kelly, M.E.M., Allosteric cannabinoid receptor 1 (CB1) ligands reduce ocular pain and inflammation. *Molecules* **2020**, 20; 25(2):417.

86. Slivicki, R.A., Iyer, V., Mali, S.S., Garai, S., **Thakur, G. A.** and Hohmann, A.G., Positive allosteric modulation of CB1 cannabinoid receptor signaling enhances morphine antinociception and attenuates morphine tolerance without altering morphine-induced dependence or reward. *Frontiers in Molecular Neuroscience*, **2020**, 28;13:54.
87. Xu, Y., Cantwell, L., Molosh, A.I., Plant, L.D., Gazgalis, D., Fitz, S.D., Dustrude, E.T., Yang, Y., Kawano, T., Garai, S., Noujaim, S.F., Shekhar, A.,*, Logothetis, D.E.,*, and **Thakur, G.A.***.The small molecule GAT1508 activates brain-specific GIRK1/2 channel heteromers and facilitates conditioned fear extinction in rodents. *Journal of Biological Chemistry,* **2020**,13;295(11):3614-3634.

88. Ben-David, Y., Kagan, S., Ben-Ami, H.C., Rostami, J., Mizrachi, T., Kulkarni, A.R., **Thakur, G.A.**,; Vaknin-Dembinsky, A., Healy, L., Brenner, T., Treinin, M. RIC3, the cholinergic anti-inflammatory pathway, and neuroinflammation *International Immunopharmacology,* **2020** Jun; 83:106381.

89. Papke R.L.*, Garai S, Stokes C, Horenstein NA, Zimmerman AD, Abboud KA, **Thakur G.A.*** Differing activity profiles of the stereoisomers of 2,3,5,6TMP-TQS, a putative silent allosteric modulator of α7nAChR. *Molecular Pharmacology*, **2020**, 98(4), 292-302.

90. Schaffer, P.C., Kulkarni, P.M., Janero, D.R., **Thakur, G.A.*** Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility. *Bioorganic and Medicinal Chemistry,* **2020**, 28(11), 115727.

91. Wilkerson, J.L., Alberti, L.B., Kerwin, A.A., Ledent, C.A., **Thakur, G.A.**, Makriyannis, A., and Milligan, E.D. Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain. *Brain and Behavior*. **2020**, Sep 25;e01850. doi: 10.1002/brb3.1850. *Online ahead of print*.

92. Timothy J. Onofrychuk, Shuang Cai, Dan L. McElroy, Andrew J. Roebuck, Quentin Greba, Sumanta Garai, **Ganesh A. Thakur**, Robert B. Laprairie, John G. Howland. Effects of the cannabinoid receptor 1 positive allosteric modulator GAT211 and acute MK-801on visual attention and impulsivity in rats assessed using the five-choice serial reaction time task. Progress in Neuropsychopharmacology and Biological Psychiatry, 2020 2021 Jul 13;109:110235. doi:10.1016/j.pnpbp.**2020**.110235. Epub 2020 Dec 26. PMID: 33373679.

93. Schaffer PC, Kulkarni PM, Janero DR, **Thakur, G.A**. Focused structure-activity relationship profiling around the 2-phenylindole scaffold of a cannabinoid type-1 receptor agonist-positive allosteric modulator: site-III aromatic-ring congeners with enhanced activity and solubility. Bioorg Med Chem. **2020** Nov 1;28(21):115727. doi: 10.1016/j.bmc.2020.115727. Epub 2020 Aug 29. PMID: 33065437

94. Wilkerson JL, Alberti LB, Kerwin AA, Ledent CA, **Thakur, G.A.**, Makriyannis A, Milligan ED. Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain. Brain Behav. **2020** Dec;10(12):e01850. doi: 10.1002/brb3.1850. Epub 2020 Sep 25. PMID: 32977358; PMCID: PMC7749576.

95. Papke RL, Garai S, Stokes C, Horenstein NA, Zimmerman AD, Abboud KA, **Thakur GA**. Differing Activity Profiles of the Stereoisomers of 2,3,5,6TMP-TQS, a Putative Silent Allosteric Modulator of a7 nAChR. Mol Pharmacol. **2020** Oct;98(4):292-302. doi: 10.1124/mol.120.119958. Epub 2020 Jul 20. PMID: 32690627; PMCID: PMC7472127.

96. Slivicki, R.A., Iyer, V., Mali, S.S., Garai, S., **Thakur, G.A.**, Crystal, J.D., Hohmann, A.G. Positive Allosteric Modulation of CB1 Cannabinoid Receptor Signaling Enhances Morphine Antinociception and Attenuates Morphine Tolerance Without Enhancing Morphine- Induced Dependence or Reward. Front Mol Neurosci. **2020** Apr 28;13:54. doi: 10.3389/fnmol.2020.00054. PMID: 32410959; PMCID: PMC7199816.

97. Ben-David, Y., Kagan, S., Cohen, Ben-Ami H., Rostami, J., Mizrahi, T., Kulkarni, A.R., **Thakur, G.A.**, Vaknin-Dembinsky A, Healy, L.M., Brenner, T., Treinin, M. RIC3, the cholinergic anti-inflammatory pathway, and neuroinflammation. Int Immunopharmacol. **2020** Jun;83:106381. doi: 10.1016/j.intimp.2020.106381. Epub **2020** Mar 14. PMID: 32179243.

98. Thapa D, Cairns EA, Szczesniak AM, Kulkarni PM, Straiker AJ, **Thakur G.A.**, Kelly MEM. Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation. Molecules. 2020 Jan 20;25(2):417. doi: 10.3390/molecules25020417. PMID: 31968549; PMCID: PMC7024337.

99. Xu Y, Cantwell L, Molosh AI, Plant LD, Gazgalis D, Fitz SD, Dustrude ET, Yang Y, Kawano T, Garai S, Noujaim SF, Shekhar A, Logothetis DE, **Thakur, G.A**. The small molecule GAT1508 activates brain-specific GIRK1/2 channel heteromers and facilitates conditioned fear extinction in rodents. J Biol Chem. 2020 Mar 13;295(11):3614-3634. doi: 10.1074/jbc.RA119.011527. Epub 2020 Jan 17. PMID: 31953327; PMCID: PMC7076198.

100. Garai S, Kulkarni PM, Schaffer PC, Leo LM, Brandt AL, Zagzoog A, Black T, Lin X, Hurst DP, Janero DR, Abood ME, Zimmowitch A, Straiker A, Pertwee RG, Kelly M, Szczesniak AM, Denovan-Wright

EM, Mackie K, Hohmann AG, Reggio PH, Laprairie RB, **Thakur GA**. Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators. J Med Chem. 2020 Jan 23;63(2):542-568. doi: 10.1021/acs.jmedchem.9b01142. Epub 2020 Jan 3. PMID: 31756109; PMCID: PMC7077750.

101. Dan L. McElroy, Andrew J. Roebuck, Gavin A. Scott, Quentin Greba, Garai S., Eileen M. Denovan-Wright, **Ganesh A. Thakur**, Robert B. Laprairie, John G. Howland. Antipsychotic potential of the type 1 cannabinoid receptor positive allosteric modulator GAT211: preclinical in vitro and in vivo studies. Psychopharmacology. (Berl). 2021 Apr;238(4):1087-1098. doi: 10.1007/s00213-020-05755-x. Epub 2021 Jan 13. PMID: 33442771

102. Gauthier AG, Wu J, Lin M, Sitapara R, Kulkarni A, **Thakur, G.A.**, Schmidt EE, Perron JC, Ashby CR Jr, Mantell LL. The Positive Allosteric Modulation of alpha7-Nicotinic Cholinergic Receptors by GAT107 Increases Bacterial Lung Clearance in Hyperoxic Mice by Decreasing Oxidative Stress in Macrophages. Antioxidants (Basel). 2021 Jan 19;10(1):135. doi: 10.3390/antiox10010135. PMID: 33477969

103. Cui M, Alhamshari Y, Cantwell L, Ei-Haou S, Eptaminitaki GC, Chang M, Abou-Assali O, Tan H, Xu K, Masotti M, Plant LD, **Thakur, G.A.**, Noujaim SF, Milnes J, Logothetis DE. A benzopyran with antiarrhythmic activity is an inhibitor of Kir3.1-containing potassium channels. J Biol Chem. 2021 Jan-Jun;296:100535. doi: 10.1016/j.jbc.2021.100535. Epub 2021 Mar 11. PMID: 33713702

104. Jiang S, Iliopoulos-Tsoutsouvas C, Tong F, Brust CA, Keenan CM, Raghav JG, Hua T, Wu S, Ho JH, Wu Y, Grim TW, Zvonok N, **Thakur, G.A.**, Liu ZJ, Sharkey KA, Bohn LM, Nikas SP, Makriyannis A. Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists. J Med Chem. 2021;64(7):3870-3884. doi: 10.1021/acs.jmedchem.0c02053.. PMID: 33761251

105. Garai S, Leo LM, Szczesniak AM, Hurst DP, Schaffer PC, Zagzoog A, Black T, Deschamps JR, Miess E, Schulz S, Janero DR, Straiker A, Pertwee RG, Abood ME, Kelly MEM, Reggio PH, Laprairie RB, **Thakur, G.A**. Discovery of a Biased Allosteric Modulator for Cannabinoid 1 Receptor: Preclinical Anti-Glaucoma Efficacy. J Med Chem. **2021** Jun 24;64(12):8104-8126. doi: 10.1021/acs.jmedchem.1c00040. PMID: 33826336

106. Roebuck, A., Greba, Q., Smolyakova, A., Alaverdashvili, M., Marks, W., Garai, S., Baglot, S., Petrie, G., Cain, S., Snutch, T., **Thakur, G.A.**, Hill, M.A., Howland, J., and Laprairie, R. Positive allosteric modulation of type 1 cannabinoid receptors reduces absence seizures in Genetic Absence Epilepsy Rats from Strasbourg. Neuropharmacology. **2021** Jun 1;190:108553. doi: 10.1016/j.neuropharm.2021.108553. Epub 2021 Apr 9. PMID: 33845076

107. Hamouda AK, Bautista MR, Akinola LS, Alkhlaif Y, Jackson A, Carper M, Toma WB, Garai S, Chen YC, **Thakur GA**, Fowler CD, Damaj MI. Potentiation of (α4)2(β2)3, but not (α4)3(β2)2, nicotinic acetylcholine receptors reduces nicotine self-administration and withdrawal symptoms. Neuropharmacology. **2021** Jun 1;190:108568. PMID: 33878302

108. Mizrachi T, Marsha O, Brusin K, Ben-David Y, **Thakur G.A.**, Vaknin-Dembinsky A, Treinin M, Brenner T. J. Suppression of neuroinflammation by an allosteric agonist and positive allosteric modulator of the α7 nicotinic acetylcholine receptor GAT107. Neuroinflammation. **2021** Apr 26;18(1):99. PMID: 33902624

109. Pismataro MC, Horenstein NA, Stokes C, Dallanoce C, **Thakur GA**, Papke RL. Stable desensitization of α7 nicotinic acetylcholine receptors by NS6740 requires interaction with S36 in the orthosteric agonist binding site. Eur J Pharmacol. **2021** Aug 15;905:174179. PMID: 34004208

110. Garai S, Schaffer PC, Laprairie RB, Janero DR, Pertwee RG, Straiker A, **Thakur, G.A**. Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure. Bioorg Med Chem. **2021** Nov 15;50:116421. doi: 10.1016/j.bmc.2021.116421. Epub 2021 Sep 25. PMID: 34634617

111. Wilkerson JL, Alberti LB, **Thakur GA**, Makriyannis A, Milligan ED. Peripherally administered cannabinoid receptor 2 (CB2R) agonists lose anti-allodynic effects in TRPV1 knockout mice, while intrathecal administration leads to anti-allodynia and reduced GFAP, CCL2 and TRPV1 expression in the dorsal spinal cord and DRG. Brain Res. **2022** Jan 1;1774:147721. PMID: 34774500

112. Anderson LL, Doohan PT, Hawkins NA, Bahceci D, Garai S, **Thakur, G.A.**, Kearney JA, Arnold JC. The endocannabinoid system impacts seizures in a mouse model of Dravet syndrome. Neuropharmacology. **2021** Nov 22;205: 108897. PMID: 34822817

113. Dan L McElroy, Andrew J Roebuck, Quentin Greba, Sumanta Garai, Asher L Brandt, Orhan Yilmaz, Stuart M Cain, Terrance P Snutch, **Ganesh A Thakur**, Robert B Laprairie, John G Howland. The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg. PMID: 35128516 PMCID: PMC8804275

114. Oliva, I., Saberi, S.A., Rangel-Barajas, C., Iyer, V., Bunner, K.D., Lai, Y.Y., Kulkarni, P.M., Garai, S., **Thakur, G.A.,** Crystal, J.D., Rebec, G.V., Hohmann, A.G. Inhibition of PSD95-nNOS protein-protein interactions decreases morphine reward and relapse vulnerability in rats. *Addict. Biol.*, 2022 Sep;27(5):e13220.

115. Gazgalis, D., Cantwell, L., Xu, Y., **Thakur, G.A.**, Cui, M., Guarnieri, F., Logothetis, D.E., Use of a Molecular Switch Probe to Activate or Inhibit GIRK1 Heteromers In Silico Reveals a Novel Gating Mechanism. *Int. J. Mol. Sci.* **2022** Sep 16;23(18):10820. doi: 10.3390/ijms231810820. PMID: 36142730 PMCID: PMC9502415

116. Iyer V, Rangel-Barajas C, Woodward TJ, Kulkarni A, Cantwell L, Crystal JD, Mackie K, Rebec GV, **Thakur G.A.**, Hohmann AG. Negative allosteric modulation of CB1 cannabinoid receptor signaling suppresses opioid-mediated reward. *Pharmacol Res.* **2022** Nov;185:106474. PMID: 36179954

117. Stokes C, Camacho-Hernandez GA, **Thakur GA**, Wu X, Taylor P, Papke RL. Differential Activation and Desensitization States Promoted by Noncanonical α7 Nicotinic Acetylcholine Receptor Agonists. J Pharmacol Exp Ther. **2022** Nov;383(2):157-171. PMID: 36279397

118. Brandt AL, Garai S, Zagzoog A, Hurst DP, Stevenson LA, Pertwee RG, Imler GH, Reggio PH, **Thakur, G.A.**, Laprairie RB. Pharmacological evaluation of enantiomerically separated positive allosteric modulators of cannabinoid 1 receptor, GAT591 and GAT593. Front Pharmacol. **2022** Oct 25;13:919605 PMID: 36386195

119. Gauthier AG, Lin M, Zefi S, Kulkarni A, **Thakur, G.A.**, Ashby CR Jr, Mantell LL. GAT107-mediated α7 nicotinic acetylcholine receptor signaling attenuates inflammatory lung injury and mortality in a

mouse model of ventilator-associated pneumonia by alleviating macrophage mitochondrial oxidative stress via reducing MnSOD-S-glutathionylation. *Redox Biol.* **2023** Apr;60:102614. PMID: 36717349

120. Berms, B, M., Sullivan, E.E., Connolly, J.G., Zhang, J., Chang, A., Ortiz, R., Cantwell, L., Kulkarni, P., Thakur, G.A., Ferris, C. F. Dose-dependent effects of GAT107, a novel allosteric agonist-positive allosteric modulator (ago-PAM) for the α7 nicotinic cholinergic receptor: a BOLD phMRI and connectivity study on awake rats. Front Neurosci, **2023**;17:1196786. doi: 10.3389/fnins.2023.1196786. eCollection 2023.

121. Dallanoce, C.; Richter, K.; Stokes, C.; Papotto, C.; Andleeb, H.; Thakur, G. A.; Kerr, A.; Grau, V.; Papke, R. L. New Alpha9 nAChR Ligands Based on a 5-(Quinuclidin-3-ylmethyl)-1,2,4-oxadiazole Scaffold. ACS Chem Neurosci **2024**, 15 (4), 827-843. DOI: 10.1021/acschemneuro.3c00720

122. Iyer, V.; Saberi, S. A.; Pacheco, R.; Sizemore, E. F.; Stockman, S.; Kulkarni, A.; Cantwell, L.; Thakur, G. A.; Hohmann, A. G. Negative allosteric modulation of cannabinoid CB (1) receptor signaling suppresses opioid-mediated tolerance and withdrawal without blocking opioid antinociception. bioRxiv **2024**. DOI: 10.1101/2024.01.06.574477

123. Oliva, I.; Kazi, F.; Cantwell, L. N.; Thakur, G. A.; Crystal, J. D.; Hohmann, A. G. Negative allosteric modulation of CB1 cannabinoid receptor signaling decreases intravenous morphine self-administration and relapse in mice. bioRxiv **2024**. DOI: 10.1101/2024.01.16.575900

124. Burke, S. M.; Avstrikova, M.; Noviello, C. M.; Mukhtasimova, N.; Changeux, J. P.; Thakur, G. A.; Sine, S. M.; Cecchini, M.; Hibbs, R. E. Structural mechanisms of alpha7 nicotinic receptor allosteric modulation and activation. ***Cell*** **2024**, 187 (5), 1160-1176 e1121. DOI: 10.1016/j.cell.2024.01.032

125. Andleeb, H. P., R.L.; Stokes, C.; Richter, K.; Herz, S.M.; Chiang, K.; Kanumuri, S.R.R.; Sharma, A.; Damaj, M.I.; Grau, V.; Horenstein, N.A.; Thakur, G. A.* (**2024**) Explorations of agonist selectivity for the a9* nAChR with novel substituted carbamoyl/amido/heteroaryl dialkylpiperazinium salts and their therapeutic implications in pain and inflammation. *J. Med. Chem.* (Just accepted).

## B. BOOK CHAPTERS:

1) **Thakur, G. A.**, Nikas, S. P., Li, C., Makriyannis, A., Structural requirements for cannabinoid receptor probes. *Handbook of Experimental Pharmacology*, **2005**, 168, 209-246.

2) **Thakur, G. A.**, Nikas, S. P., Duclos, R. I., Jr., Makriyannis, A. Methods for the synthesis of cannabinergic ligands. *Methods in Molecular Medicine*, **2006**, 123, 113-148.

3) Kulkarni A.R., Garai S., Janero D.R., **Thakur G.A.***. Design and Synthesis of Cannabinoid 1 Receptor (CB1R) Allosteric Modulators: Drug Discovery Applications. *Methods Enzymol.* **2017**; 593:281-315.

4) Garai, S. and **Thakur, G.A.*** Copper-assisted Cyanation Reactions, Garai In *Copper Catalysis in Organic Synthesis*, Wiley-VCH, 2020.

## C. PATENTS:

1. Alexandros Makriyannis, Spyros P. Nikas, Atmaram Khanolkar, **Ganesh A. Thakur** and Dai Lu, (**2007**) Methods of preparations and use of novel bicyclic cannabinoids, PCT Int. Appl. U.S. Patent Application No. 10/483,482, US 2007135388.

2. Alexandros Makriyannis, **Ganesh A. Thakur**, Rishi Sharma. Cannabinoids with controlled detoxification (US19539292, August 2012)
3. Alexandros Makriyannis, Marsha D'Souza, Shama Bajaj, Spyros Nikas, **Ganesh A. Thakur**

   Novel resorcinol derivatives as cannabinergic ligands. Application No.61714914, October 2012.
4. **Ganesh A. Thakur** and Pushkar M. Kulkarni, Allosteric Modulators of CB1 Cannabinoid Receptor, PCT/US13/20543; Filed January 7, 2013 (provisional date: January 2012)
5. **Ganesh A. Thakur**, Ritesh, B. Tichkule, Pushkar M. Kulkarni, Abhijit R. Kulkarni "Allosteric Modulators of CB1 Cannabinoid Receptor" PCT/US2014/052304, Date of Filing: August 22, 2014 (Provisional Date: August 22, 2013)
6. **Ganesh A. Thakur**, Abhijit R. Kulkarni and Roger L. Papke. "Novel Ligands for the α7 Nicotinic Acetylcholine Receptors" US Provisional Application No. 62/028, Date of Filing: July 23, 2014
7. **Ganesh A. Thakur**, Diomedes Logothetis, Anantha Shekhar, Lucas Cantwell. "Compounds for the Treatment of Post-Traumatic Stress Disorder" US Provisional Application No. 62683424, Date of Filing: June 11, 2018.
8. **Ganesh A. Thakur** & Sumanta Garai. "*N*-Substituted Indoles and Use as Allosteric Modulators of Cannabinoid Receptors". PCT Application No. PCT/US2019/039354. Date of filing June 26, 2019.
9. **Ganesh A. Thakur** & Hina Andleeb. "Novel alpha 9/alpha10 and alpha7 nicotinic acetylcholine receptor ligands". Provisional Patent Application filed on May 3, 2024

## D. CONFERENCES

1. Synthesis of tetrasaccharide of Erylusamine-B, by **Ganesh A. Thakur** and K.G. Akamanchi. presented in XIIIth Carbohydrate Conference, conducted by Forest Research Institute in collaboration with Association of Carbohydrate Chemists & Technologist, India in Nov. 1998.

2. A novel catalytic approach for selective anomeric deacetylation of per-O-acetylated aldoses, by **Ganesh A. Thakur** and K.G. Akamanchi, in XIVth Carbohydrate Conference conducted by Indian Institute of Technology in collaboration with Association of Carbohydrate Chemists & Technologists, India in Dec-1999.
3. Selective anomeric deacetylation of per-O-acetylated aldoses by catalytic iodine in methanol, by **Ganesh A. Thakur** and K.G. Akamanchi, International Conference on Chemistry and 36th Annual Convention of Chemists conducted by Indian Chemical Society and Indian Association for Cultivation of Sciences (IACS) in Calcutta, India, in Dec.1999.
4. Hypervalent iodine compound mediated bromoacetoxylation of olefinic natural products, by Sachin S. Chaudhari, G.V. Ramanarayanan, **Ganesh A. Thakur** and K. G. Akamanchi, 5th IUPAC International Symposium on Bioorganic Chemistry, conducted by International Union of Pure and Applied Chemistry at National Chemical Laboratory, Pune, India in Jan-Feb 2000.

5. Total Synthesis of Erylusamine-B - A potent Interleukin-6 Antagonist, by **Ganesh A. Thakur**, Smita G. Kavishwar and K.G. Akamanchi, 5th IUPAC International Symposium on Bioorganic Chemistry, conducted by International Union of Pure and Applied Chemistry at National Chemical Laboratory, Pune, India in Jan-Feb 2000.

6. New efficient synthesis of deuterated 5-alkylresorcinols and their application in the preparation of $\Delta^9$-THC, $\Delta^9$-THCV, and their metabolites by Spyros Nikas, **Ganesh A. Thakur**, Alexandros Makriyannis, in 222nd ACS National Meeting, Chicago, IL, United States, Aug. 2001.

7. Adamantyl cannabinoids, by Dai Lu, **Ganesh A. Thakur**, Peter J. McLaughlin, Lynn A. Swezey, Keisha M. Winston, Ania Wisniecki, John D. Salamone, Toby U. C. Jarbe, Patricia H. Reggio, Clifford George, Alexandros Makriyannis, 13th Annual International Cannabinoid Research Society (ICRS) Symposium, Cornwall, Ontario, Canada, June 2003.

8. A comparision of the novel CB1 agonist AM411 with the muscarinic antagonist Scopolamine a spatial discrimination task in rats by P. J. McLaughlin, K. M. Winston, L. A. Swezey, D. Lu, **G. A. Thakur**, A. Makriyannis, J. D. Salomone, Washington, DC: Society for neuroscience, 2004.

9. Some behavioral effects of the novel CB1-receptor agonist AM 411 in squirrel monkeys, by M. S. Delatte, M. Zielstroff, **G. Thakur**, A. Makriyannis, and J. Bergman, CPDD 67$^{th}$ annual meeting, Orlando, FL, June 18-23, 2005. McLean Hospital, Belmont, MA and University of Connecticut, Storrs, CT.

10. Synthesis and SAR of CB1 selective classical/non-classical hybrid cannabinoids, **Ganesh A. Thakur** and Alexandros Makriyannis, 229th ACS National Meeting, San Diego, CA, United States, March 13-17, 2005.

11. A ligand based structural biology approach for the characterization of the cannabinoid receptor binding domains, by John Williamns, Suma Yaddanapudi, Wei Xu, **Ganesh A. Thakur**, Nikolai Zvonok, Paul Vouros, Alexandros Makriyannis, 54$^{th}$ ASMS Conference on mass Spectrometry, in May-June 2006, Seattle, Washington. *FASEB J.* 2007 21:631.6.

12. Physiological and behavioral effects of novel CB1-receptor agonists AM 411 and AM 4054 in monkeys, by M.S. Delatte, **G.A. Thakur**, M. Riolo, A. Makriyannis and J. Bergman, Experimental Biology (Advancing the biomedical frontier), San Francisco, California, April 1-5, 2006.

13. Physiological and behavioral effects of novel CB1-receptor agonists AM 411 and AM 4054 in monkeys, by Marcus S Delatte, **G.A. Thakur**, Matthew Riolo, Alexandros Makriyannis, and Jack Bergman, Experimental Biology Annual Meeting, Washington, D.C. April 28-May2, 2007 *FASEB J.* 2006 20:A682.

14. Discriminative stimulus effects of methamphetamine and in vivo microdialysis in rat, by R. I. Desai, C. A. Paronis, A. Makriyannis, **G. A. Thakur**, and J. Bergman, Experimental Biology Annual Meeting, Washington, D.C. April 28-May2, 2007, *FASEB J.* 2007 21:715.3

15. Partial agonist and antagonist effects of $\Delta^9$-tetrahydrocannabinol ($\Delta^9$THC) in Rats, by Carol A Paronis; **Ganesh A Thakur**; Kiran Vemuri; Alex Makriyannis; Jack Bergman, Experimental Biology Annual Meeting, Washington, D.C. April 28-May2, 2007, *FASEB J.* 2007 21:562.2

16. Effects of a Selective Cannabinoid Agonist and Antagonist on Body Temperature in Rats, by Carol A Paronis; **Ganesh A Thakur**; Kiran Vemuri; Alex Makriyannis; Jack Bergman, Experimental Biology Annual Meeting, Washington, D.C. April 28-May 2, 2007, *FASEB J.* 2007 21:562.1

17. Synthesis of (-)-$\Delta^9$-tetrahydrocannabinol and (-)-$\Delta^9$-tetrahydrocannabivarin metabolites and their regiospecifically deuterated analogs, by Nikas, Spyros P.; **Thakur, Ganesh A.**; Parish, Damon; Alapafuja, Shakiru O.; Huestis, Marilyn A.; Makriyannis, Alexandros. Abstracts of Papers, 234th ACS National Meeting, Boston, MA, United States, August 19-23, 2007, MEDI-031

18. Diuretic effect of cannabinoid agonists, by Carol A. Paronis, J. Martin, J. Bergman, **G. A. Thakur**, A. Zvonok and A. Makriyannis 12$^{th}$ European Behavioural Pharmacology Society, Tübingen, Germany, Aug 31-Sept 03, 2007.

19. New and efficient synthesis of regiospecifically deuterated covalent probes for cannabinoid receptors, by **Thakur Ganesh A.**; Sharma, Rishi; Makriyannis, Alexandros, 240th ACS National Meeting, Boston, MA, United States, August 22-26, 2010, MEDI 63.
20. Hybrid adamantyl cannabinoids by Bajaj, Shama; **Thakur G.A.**; Tichkule, Ritesh; Makriyannis, Alexandros, 240th ACS National Meeting, Boston, MA, United States, August 22-26, 2010, MEDI-370.
21. Structure activity relationship study of BAY 59-3074, a partial agonist of the CB1 cannabinoid receptor by Teng, Heidi; **Thakur, Ganesh A.**; Makriyannis, Alexandros. 240th ACS National Meeting, Boston, MA, United States, August 22-26, 2010, MEDI-353.
22. Conformationally constrained analogs of BAY 59-3074, a CB1 cannabinoid receptor partial agonist by Teng, Heidi; **Thakur, G. A**., Makriyannis, Alexandros. 240th ACS National Meeting, Boston, MA, United States, August 22-26, 2010, MEDI-216.
23. The cannabinoid-1 (CB1) agonist AM841 slows GI motility in the rat by peripheral actions. *R. Abalo*, C. Chen, G Vera, M.A. Castillo, J. Fichna, **G.A. Thakur**, A. Makriyannis, M.I. Martín, M Storr. Neurogastroenterology and Motility Joint International meeting (NGM), August 26-29, 2010 Boston, MA.
24. Cannabinoid CB2 receptors activation suppresses neuropathic pain evoked by the chemotherapeutic agent cisplatin in rats by Josée Guindon, Spyridon Nikas, **Ganesh A. Thakur**, V. Kiran Vemuri, Alexandros Makriyannis and Andrea G. Hohmann. 21st Annual symposium of the International Cannabinoid Research Society, St. Charles, IL, USA, July 05-10, 2011.
25. Intrathecal cannabinoid receptor 2 (CB2) agonists alter spinal and dorsal root ganglion inflammatory factors in neuropathic rats, by Jenny L. Wilkerson, Ellen C. Dengler, James A. Wallace, Audra A. Kerwin, **Ganesh A. Thakur**, Alexandros Makriyannis, and Erin D. Milligan. 21st Annual symposium of the International Cannabinoid Research Society, St. Charles, IL, USA, July 05-10, 2011.
26. Amino acids D2.63 and K373 are important for maintaining the CB1R binding pocket, while residues K3.28 and S1.39 are involved in selective ligand recognition, by Jahan P. Marcu, Ankur Kapur, Megan Trznadel, Patricia H. Reggio, **Ganesh A. Thakur**, Alexandros Makriyannis, and Mary E. Abood. 21st Annual symposium of the International Cannabinoid Research Society, St. Charles, IL, USA, July 05-10, 2011.
27. Cannabinoid and κ-opioid mediated diuresis in rats, by Carol A. Paronis, **Ganesh A. Thakur**, and Alexandros Makriyannis. 21st Annual symposium of the International Cannabinoid Research Society, St. Charles, IL, USA, July 05-10, 2011.
28. Diuresis: a simple and efficient measure to screen cannabinoids, by Girish R Chopda, Joseph B Anderson, **Ganesh A Thakur**, Alexandros Makriyannis, and Carol A Paronis. 21st Annual symposium of the International Cannabinoid Research Society, St. Charles, IL, USA, July 05-10, 2011.
29. The selective cannabinoid receptor 2 ($CB_2R$) agonist AM1710 acts independently of cannabinod receptor 1 ($CB_1R$) responses in neuropathic mice. Jenny L. Wilkerson, Ellen C. Dengler, James A. Wallace, Audra A. Kerwin, Lauren B. Alberti, Brandi Bowman, Pamela S. Platero, **Ganesh A. Thakur**, Alexandros Makriyannis, Erin D. Milligan. Society of Neuroscience meeting, Washington, D.C., USA, November 12-16, 2011.
30. Selective activation of cannabinoid CB2 receptors suppresses chemotherapy-induced neuropathy independent of CB1 or CXCR4 receptor signaling. Deng, L., Guindon, J., Makie, K., White, F., **Thakur,**

**G.A**., Makriyannis, A., and Hohmann, A.G. 22nd Annual symposium of the International Cannabinoid Research Society, Freiburg, Germany, July 22-27, 2012.

31. Selective activation of cannabinoid CB2 receptors suppresses the maintenance of chemotherapy-induced neuropathy and is independent of CB1 signaling. Deng, L., Guindon, J., **Thakur, G.A**., Makriyannis, A., Mackie, K., and Hohmann, A.G. Society for Neuroscience, 2012.
32. Positive Allosteric Modulators of CB1 as Pharmacotherapy of Anorexia Nervosa. Kulkarni, P. M., Jarbe, T.U., Goldberg, S., Barbarich-Marsteller, N., **Thakur, G. A.**, RISE, NEU, Boston, 2013
33. Identification of a Potent Modulator of Nicotinic α7Acetylcholine Receptors for the Treatment of Cognitive Disorders. Kulkarni, A. R., Deschamps, J.R., Papke R.L and **Thakur, G. A.** RISE, Northeastern Univ. Boston, March 22nd, 2013
34. Novel positive allosteric modulators of CB1 cannabinoid receptor for the treatment of anorexia nervosa By Kulkarni, Pushkar M.; Jarbe, Torbjorn; Goldberg, Steven; Barbarich-Marsteller, Nicole r; **Thakur, Ganesh A.** From Abstracts of Papers, 246th ACS National Meeting & Exposition, Indianapolis, IN, United States, September 8-12, 2013 (2013), MEDI-84.
35. Stereochemical requirements within the tetrahydroquinoline scaffold for the positive allosteric modulation at alpha7 nicotinic acetylcholine receptors. Kulkarni, Abhijit R.; Deschamps, Jeffrey; Papke, Roger L.; **Thakur, Ganesh A.** From Abstracts of Papers, 246th ACS National Meeting & Exposition, Indianapolis, IN, United States, September 8-12, 2013 (2013), MEDI-83.
36. Mutations of α7 nAChR W55 enhance the allosteric agonism of GAT107, the active isomer of 4BP-TQS, and decouple interactions between orthosteric and allosteric sites. R. L. Papke, N. A. Horenstein, C. Stokes, Cheol-Young Maeng, A. R. Kulkarni, and **G. A. Thakur**, Society for Neuroscience, New Orleans, LA, November 10, 2013.
37. Modifying CB1 receptor signaling to reduce IOP in a mouse model of ocular hypertension. Elizabeth A. Cairns, Michele L. Archibald, Alex J. Straiker, Pushkar M. Kulkarni, **Ganesh A. Thakur**, William H. Badridge and Melanie E.M. Kelly, International Cannabinoid Research Society (ICRS), Braveno, Italy, June 28-July 3, 2014.
38. Design, Synthesis and Biochemical Evaluation of Novel Electrophilic and Photoaffinity Covalent Probes to Map the CB1 Receptor Allosteric Site(s). Kulkarni, A. R., Pushkar M. Kulkarni, Anisha Korde, Nikolai Zvonok, Maria G. Cascio, Alexandros Makriyannis, Roger Pertwee and **Ganesh A. Thakur**. World Pharma Congress 2014, Boston, USA.
39. Positive allosteric modulation of CB1 with GAT211 suppresses paclitaxel-induced neuropathic pain while by passing unwanted side effects of CB1 receptor activation. Richard A. Slivicki, Liting Deng, Pushkar M. Kulkarni, Maria Cascio, Roger G. Pertwee, **Ganesh A. Thakur** and Andrea G. Hohmann. International Cannabinoid Research Society (ICRS), Braveno, Italy, June 28-July 3, 2014.
    **** This work received the best presentation award.***
40. Silent and Allosteric Agonists of α7Acetylcholine Receptors for the Treatment of Inflammation and Neuropathic Pain. R. L. Papke, N. A. Horenstein, C. Stokes, Cheol-Young Maeng, Abhijit. R. Kulkarni, and **Ganesh A. Thakur**, Nicotinic Acetylcholine Receptor 2014 Conference, Cambridge (London), UK.
41. Expeditious Microwave-assisted Synthesis of 4BP-TQS, an ago-PAM of α7 nAChRs, its Stereochemical Requirement and the Target Amino Acids Responsible for Activity. Abhijit R. Kulkarni, Nicole A. Horenstein, Clare Stokes, Lu W Corrie, Cheol-Young Maeng, Jeffrey Deschamps, Roger L.

Papke, **Ganesh A. Thakur** American Association of Pharmaceutical Scientists' (AAPS) NorthEast Regional Discussion Group (NERDG), Connecticut, USA, 2014
**** This work received the best presentation award.***

42. Enantiomer-specific positive allosteric modulation of the type 1 cannabinoid receptor for the treatment of Huntington's disease. Robert B. Laprairie, Adel Zrein, Amina M. Bagher, Pushkar M. Kulkarni, **Ganesh A. Thakur**, Melanie E. Kelly, and Eileen M. Denovan-Wright, International Cannabinoid Research Society (ICRS), Wolfville, Canada, 2015.
**** This work received the best oral presentation award.***

43. Actions of the ago-PAM GAT211 and its enantiomer GAT229 on intraocular pressure and retinal ganglion cell loss in the nee mouse model of ocular hypertension. Elizabeth A. Cairns, Alex J. Straiker, Pushkar M. Kulkarni, Ganesh A. Thakur, William H. Badridge, and Melanie E.M. Kelly. International Cannabinoid Research Society (ICRS), Wolfville, Canada, 2015.

44. Design, synthesis and biochemical evaluation of novel electrophilic and photoaffinity covalent probes to map the CB1receptor allosteric site(s). Abhijit R. Kulkarni, Pushkar M. Kulkarni, Anisha Korde, Nicolai Zvonok, Maria Cascio, Alexandros Makriyannis, Roger G. Pertwee and **Ganesh A. Thakur**. International Cannabinoid Research Society (ICRS), Wolfville, Canada, 2015.
**** This work received the best oral/poster presentation award.***

45. Fluorine-walk on GAT211, A Positive Allosteric Modulator of the Cannabinoid 1 Receptor: Identification of Critical Sites for Advancing Structure-activity Relationship Studies. Pushkar M. Kulkarni, Sumanta Garai, Robert B. Laprairie, Melanie Kelly, Eileen Denovan-Wright, Lesley A. Stevenson, Roger Pertwee, **Ganesh A. Thakur**, ICRS, 2016.

46. Mapping Cannabinoid Receptor 1 Allosteric Site(S): Critical Molecular Determinant And Signaling Profile Of GAT100 - A Novel, Potent And Irreversibly Binding Probe. Robert B. Laprairie, Abhijit R. Kulkarni, Pushkar M. Kulkarni, Dow P. Hurst, Diane Lynch, Patricia H. Reggio, David R. Janero, Roger G. Pertwee, Lesley A. Stevenson, Melanie E. M. Kelly, Eileen M. Denovan-Wright, and **Ganesh A. Thakur**, ICRS, 2016.

47. Positive Allosteric Modulators of CB1 Receptor Signaling Produce Synergistic Antinociceptive Effects with Inhibitors of Fatty-Acid Amide Hydrolase And Monacylglyerol Lipase. Richard A. Slivicki, Pushkar M. Kulkarni, Ken Mackie, **Ganesh A. Thakur** and Andrea G. Hohmann. ICRS, 2016

48. Highly efficient, one-pot and scalable microwave-accelerated synthesis of urea derivatives via Curtius rearrangement. Abhijit R. Kulkarni, Sumanta Garai, **Ganesh A. Thakur**, *Chemistry and Pharmacology of Drugs of Abuse*, Northeastern University, Boston, 2016.

49. Novel Pharmacotherapy for Treating Cognitive Dysfunction and Chronic Pain in Alzheimer's disease. Abhijit R. Kulkarni, Qi Ye, Deniz Bagdas, Jonghan Kim, Roger L. Papke, Imad Damaj, **Ganesh A. Thakur**, *Chemistry and Pharmacology of Drugs of Abuse*, Northeastern University, Boston, 2016.

50. Mapping Cannabinoid Receptor 1 Allosteric Site(S): Critical Molecular Determinant And Signaling Profile Of GAT100 - A Novel, Potent And Irreversibly Binding Probe. Robert B. Laprairie, Abhijit R. Kulkarni, Pushkar M. Kulkarni, Dow P. Hurst, Diane Lynch, Patricia H. Reggio, David R. Janero, Roger G. Pertwee, Lesley A. Stevenson, Melanie E. M. Kelly, Eileen M. Denovan-Wright, and **Ganesh A. Thakur**, *Chemistry and Pharmacology of Drugs of Abuse*, Northeastern University, Boston, 2016.

51. Positive Allosteric Modulators of CB1 Receptor Signaling Produce Synergistic Antinociceptive Effects With Inhibitors Of Fatty-Acid Amide Hydrolase And Monacylglyerol Lipase. Richard A. Slivicki, Pushkar M. Kulkarni, Ken Mackie, **Ganesh A. Thakur** and Andrea G. Hohmann. *Chemistry and Pharmacology of Drugs of Abuse, 2016*, NEU, Boston.

52. Highly efficient, one-pot and scalable microwave-accelerated synthesis of urea derivatives via Curtius rearrangement. Abhijit R. Kulkarni, Sumanta Garai, **Ganesh A. Thakur** *Research Showcase* 2016, Department of Pharmaceutical Sciences, BCHS, NEU, Boston.

53. Mapping Cannabinoid Receptor 1 Allosteric Site(S): Critical Molecular Determinant and Signaling Profile of GAT100 - A Novel, Potent and Irreversibly Binding Probe. Robert B. Laprairie, Abhijit R. Kulkarni, Pushkar M. Kulkarni, Dow P. Hurst, Diane Lynch, Patricia H. Reggio, David R. Janero, Roger G. Pertwee, Lesley A. Stevenson, Melanie E. M. Kelly, Eileen M. Denovan-Wright, and **Ganesh A. Thakur**. *Research Showcase* 2016, Department of Pharmaceutical Sciences, BCHS, NEU, Boston.

54. Effects of the type 1 cannabinoid receptor positive allosteric modulator GAT211 on absence seizures and the anxiety-like phenotype of genetic absence epilepsy rats from Strasbourg. Mariam Alaverdashvili, Quentin Greba, Michael Anderson, Andrew J. Roebuck, Wendie N. Marks, Sumanta Garai, Terrance P. Snutch, **Ganesh A. Thakur**, John G. Howland, and Robert B. Laprairie. Presented at the International Cannabinoid Research Society Conference (Leiden, July 31).

55. Positive allosteric modulation Of CB1 receptor signaling to lower intraocular pressure. Anna-Maria Szczesniak, Anaelle Zimmowitch, Laura Daily, Ken Mackie, Alex Straiker, Peter Schaffer, Sumanta Garai, **Ganesh A. Thakur,** and Melanie Kelly. Presented at the International Cannabinoid Research Society Conference, Leiden, July 31, 2018.

56. Positive allosteric modulation of CB1 cannabinoid receptor signaling Enhances the anti-allodynic effects of morphine and attenuates morphine tolerance. Richard A. Slivicki, Sonali S. Mali, Sumanta Garai, **Ganesh A. Thakur,** and Andrea G. Hohmann. Presented at the International Cannabinoid Research Society Conference, Leiden, July 31, 2018.

57. Exploring the structure-activity relationship of type 1 cannabinoid receptor positive allosteric modulators via "fluorine-walk". Robert B Laprairie, Sumanta Garai, Pushkar M Kulkarni, Eileen M Denovan-Wright, and **Ganesh A. Thakur**. Presented at the Canadian Society for Chemistry Conference Edmonton, May 27, 2018.

58. Structure-activity relationship of CB1R positive allosteric modulators via "fluorine walk". Sumanta Garai, Peter Schaffer, Pushkar M. Kulkarni, Robert B Laprairie, Anna-Maria Szczesniak, Eileen M Denovan-Wright, Alex Straiker, Roger Pertwee, Melanie Kelly, and **Ganesh A. Thakur**. Presented at the CPDA Conference, Boston, August 1-2, 2018.

59. Development of GAT1508, a Novel Subtype Selective Positive Allosteric Modulator (PAM) for GIRK1/2 Channels as a Novel Pharmacotherapy for Post-Traumatic Stress Disorder. Lucas N. Cantwell, Yu Xu, Yuchen Yang, Sumanta Garai, Abhijit R. Kulkarni, Takeharu Kawano, Leigh Plant, Anantha Shekhar, Diomedes Logothetis, **Ganesh A. Thakur**. Presented at the CPDA Conference Boston, August 1-2, 2018.

60. Discovery of highly biased novel positive allosteric modulators of CB1R. Sumanta Garai, Pushkar M. Kulkarni, Peter Schaffer, Robert B Laprairie, Anna-Maria Szczesniak, Alex Straiker, Roger Pertwee Melanie Kelly and **Ganesh A. Thakur**. Presented at the CPDA Conference, Boston, August 1-2, 2018.

61. Synthesis and Biological Characterization of Novel Ago-PAM of α7 nAChR, B-973 as a Non-addictive Pain Pharmacotherapy. Sumanta Garai, Krishnamohan Raja, Roger Papke, M. Imad Damaj, **Ganesh A. Thakur.** Presented at *Research Showcase*, Department of Pharmaceutical Sciences, NEU, Boston, June 12, 2018.
62. Development of GAT1508 a Novel Subtype Selective Positive Allosteric Modulator (PAM) for GIRK1/2 Channels as a Novel Pharmacotherapy for Post-Traumatic Stress Disorder. Lucas N. Cantwell, Yu Xu, Yuchen Yang, Sumanta Garai, Abhijit R. Kulkarni, Takeharu Kawano, Leigh Plant, Anantha

Shekhar, Diomedes Logothetis, **Ganesh A. Thakur**. Presented at *Research Showcase*, Department of Pharmaceutical Sciences, Boston, June 12, 2018.

63. The small molecule GAT1508 activates brain-specific GIRK1/2 heteromers and facilitates extinction of conditioned fear. Yu Xu, Lucas Cantwell, Andrei I. Molosh, Leigh D. Plant, Dimitris Gazgalis, Stephanie D. Fitz, Erik T. Dustrude, Yuchen Yang, Takeharu Kawano, Sumanta Garai, Sami F. Noujaim, Anantha Shekhar, Diomedes E. Logothetis, **Ganesh A. Thakur**. Pharm Sci Research Showcase 2019, Northeastern University, Boston.

64. Mapping the GAT211 Scaffold *via* a Fluorine- and Nitrogen-Walk Approach
Sumanta Garai, Pushkar M. Kulkarni, Peter C. Schaffer David R. Janero, **Ganesh A. Thakur**. Pharm Sci Research Showcase 2019, Northeastern University, Boston.

65. Safer and Effective Pharmacotherapy for Glaucoma through CB1R Biased Ago-PAM. Sumanta Garai, Peter C. Schaffer, Anna-Maria Szczesniak, Luciana M. Leo, Ayat Zagzoog, Asher L Brandt, Tallan Black, Jeffrey R. Deschamps, Alex Straiker, Roger G. Pertwee, Mary E. Abood, Melanie E. M. Kelly, Robert B. Laprairie, and **Ganesh A. Thakur**. Pharm Sci Research Showcase 2019, Northeastern University, Boston.

66. Novel Selective and Potent PAMs of α4β2 nAChR as a Pharmacotherapy for Nicotine addiction. Sahil Seth, Sumanta Garai, and **Ganesh A. Thakur**. Pharm Sci Research Showcase 2019, Northeastern University, Boston.

67. A Comprehensive Investigation of the CB1R Positive Allosteric Modulator, GAT211, by Structural Modifications and Computational Simulations Peter Schaffer, Pushkar Kulkarni, and **Ganesh A. Thakur**. Pharm Sci Research Showcase 2019, Northeastern University, Boston.

## III. RESEARCH FUNDING INFORMATION:

**Currently active grants:**

**1. 2R01GM057481-17 NIH/NIGMS**
Title: Targeting the Alpha7 nAChR for Therapeutic Effects
**Role: Co-I (PI on subcontract)**
Date: 03/01/2020- 02/28/2024
**Thakur Lab: $68,000 (for Yr. 2022)**
The proposal aims to develop novel compounds (ago-PAMs and silent agonists) selectively targeting α7 nAChR with desired cytokine profiles and good predicted pharmacokinetic properties and advance them into animal models of neuropathic and inflammatory pain.

**2. Canadian Institutes of Health Research (CIHR)**
Title: Development of Novel Type 1 Cannabinoid Receptor Positive Allosteric Modulators for Infantile Spasms
**Role: Co-I (PI: Dr. Robert Laprairie)**
Date: 05/01/2020- 05/30/2025
Project Total Cost: $692,325
**Direct Cost only (Thakur Lab): $100,000**
This project examines the development of CB1 receptor positive allosteric modulators (PAMs) and their possible use in the treatment of Infantile Spasms, a debilitating form of epilepsy that occurs mainly in

the young for which current treatments are largely inadequate. The Aims of the study are to characterize the CB1R allosteric modulator binding site (1) as well as the in vivo effects of novel CB1R PAMs (2), and finally to test these new drugs in two relevant animal models of epilepsy (3).

3. **RO1HL059949-23 NIH/NHLBI**
   Title: Structural Determinants of PIP2 Regulation
   **Role: Co-I (PI- Dr. Logothetis)**
   Date: 07/01/2020- 06/30/2024
   Total Requested Cost: $3,865,654.
   **Total Cost (Thakur Lab) = $353,400**
   The proposal aims to set the stage in coupling the molecular insights of small molecule regulators of activity to specifically reverse the PKC-mediated overstimulation of GIRK channel activity. Our small molecule inhibitors will be tested in transgenic models of PKC-mediated AF with the goal to dial down the aberrant activity enough to correct the AF problem without compromising cardiac health.

**Recently completed grants:**

1. **1R01 EY024717-01/NIH-NEI**
   Title: A Novel Pharmacotherapy for Glaucoma
   **Role: PI**
   Date: 09/01/2014- 08/31/2021 (NCE)
   **Total Cost: $2,207,605**
   The goal of this proposal is to optimize 2-phenylindole class of CB1 Positive Allosteric Modulators and establish the therapeutic utility of optimized candidates in reducing IOP and neuroprotection of RGCs in animal models.

2. **R43MH103936 NIH/NIMH**
   Title: Novel treatment of posttraumatic stress disorder (PTSD)
   Role: PI on the subcontract / Anagin Inc. (primary recipient)
   Date: 08/01/2014-07/31/2016
   **Total Cost = $160,000**
   The objective of this project is to develop selective and potent, small molecule inhibitors of nNOS-PSD95 protein-protein interaction for treating post-traumatic stress disorder.

3. **RO3 DA027113 NIH/NIDA**
   Early Career Development Award in Chemistry of Drug Abuse and Addiction
   Title: Allosteric Modulators of CB1 Cannabinoid Receptor
   Role: PI; Date: 08/01/2009-07/31/2013
   **Total Cost = $390,000**
   The primary goal of this project is to develop high affinity, potent and efficacious negative allosteric modulators of the CB1 receptor, based on structure of the current lead PSNCBAM-1.

4. **Undergraduate Research Creative Endeavor Award**
   Student Name: Mr. Ethan Rawl
   My Role: Mentor
   Title: Positive Allosteric Modulators of CB1R for Treating Neuropathic Pain
   **Total Cost: $3000**
   Date: November 2018

5. **R01CA206028 NIH/NCI**
   Title: (PQ9) Mitigation of Chemotherapy Induced Peripheral Neuropathy

Role: PI on the subcontract/Dr. David Gewirtz; VCU (Primary recipient)
Date: 04/15/2016-03/31/2017
Total Cost = $1,733,136
**Total Cost (Thakur Lab year 1 only) = $88,257**
The objective of this project is to test utility of α7 nAChR silent agonists and partial agonists to prevent or ameliorate the development of peripheral neuropathy induced by chemotherapy drugs cisplatin and paclitaxel.

6. **Undergraduate Research Creative Endeavor Award**
   **Northeastern University Provost's Office**
   Student Name: Ms. Angela Sung
   My Role: Mentor
   Title: Novel Allosteric Modulators of CB1R Receptor
   **Total Cost: $3000**
   Date: December 2016

7. **R01DA026795 NIH/NIDA**
   Title: Novel Medications for Cannabis Dependence
   Role: Co-Investigator; Makriyannis (PI);
   Date: 07/15/2009- 05/31/2014
   **Total Direct Cost: $397,860/year** to CDD.
   The goal of this project is to develop novel medications for the clinical management of cannabis dependence and addiction. In this work, we developed compounds with improved 'druggability', i.e., predictable and controllable time course and inactivation through detoxification to inactive metabolic products.

8. **Davis Foundation Post-doc Fellowship Program in Eating Disorder Research**
   Title: Positive Allosteric Modulators of CB1 Cannabinoid Receptor for treatment of Anorexia Nervosa. (Dr. Pushkar Kulkarni, postdoctoral fellow)
   Role: Mentor
   Date: 07/01/2012- 06/30/2015
   **Total Cost: $153,000**.

9. **Indo-US Singh Obama Post-doctoral Fellowship Program**
   Title: Development of peripherally acting CB2-selective ligands.
   (Dr. Ganesh Chaturbhuj, post-doctoral fellow)
   Role: Mentor
   Date: 10/01/2013- 09/30/2014
   **Total Cost = $30,000**

## IV. MAJOR COMMITTEE ASSIGNMENTS

### A. Service to the Department of Pharmaceutical Sciences, School of Pharmacy and BCHS.

| | |
|---|---|
| 2011- 2013 | Member, Faculty Research Development and Mentoring. |
| 2012- current | Scholarship and Award Committee (SOP). |
| 2012 | John Neumeyer Award Committee (Pharm Sci). |
| 2013-current | Assessment Committee (SOP). |

| | |
|---|---|
| 2013-Present | Pharm Sci Research Showcase – coordinator (Pharm Sci) |
| 2017-2018 | BCHS Faculty Council (BCHS) |
| 2013-2017 | Member, Merit Review Committee (Pharm Sci) |
| 2015-current | Faculty Development and Recognition Committee (BCHS) |
| 2015-current | Faculty Development Committee (BCHS) |
| 2018- current | Curriculum committee (SOP) |
| 2018- current | Executive committee (SOP) |
| 2017- current | Dean's Leadership Team (BCHS) |
| 2017-2018 | Vice Chair, Department of Pharmaceutical Sciences |
| 2018-2020 | Interim Chair, Department of Pharmaceutical Sciences |
| 2020- current | Chair, Department of Pharmaceutical Sciences |

**B. <u>NIH and International Grant Committees:</u>**

| | |
|---|---|
| 2014 | NIH Study Section, Drug Discovery for the Nervous System, Ad Hoc reviewer, June 2014 |
| 2014 | NIH Study Section, Special Emphasis Panel, Molecular Probes, June 2014 |
| 2014 | NIH Study Section, DDNS, Ad Hoc reviewer, October 2014 |
| 2014 | NIH Study Section, Special Emphasis Panel, Molecular Probes, Ad Hoc Reviewer, 2014 |
| 2016-2017 | RRD8 Study Section, Career Development Award Review Committee, US Department of Veteran Affairs, Ad Hoc Reviewer |
| 2016 | NIH, Behavioral Neuroscience Fellowship Study Section, ZRG1 F02A-K (20) |
| 2016 | NIH Study Section, Small Business: Drug Discovery for Aging, Neuropsychiatric and Neurologic Disorders, ZRG1 ETTN-M (11). |
| 2017 | Auckland Medical Research Foundation, Auckland, NZ. |
| 2017 | Research Council UK (RCUK) |
| 2019 | Member of NIH Study Section, SBIR/STTR Review Panel; ZRG1 BCMB-G (10) B; Drug Discovery & Development |
| 2020- | Member of NIH Study Section, Special Emphasis Panel: Step Up for Substance Use Disorders (SUD)- A Drug Target Initiative for Scientists Engaged in Fundamental Research; U18 Grants. |
| 2022 | New Zealand Government's Marsden Funds (July 2022). |
| 2022 | NIH Study Section, Drug Discovery for the Nervous System, Ad Hoc reviewer, June 2022 |
| 2022 | NINDS Special Emphasis Panel, ZNS1 SRB-R (03), Initial Translation Efforts for Non addictive Analgesic Therapeutics Development (HEAL U19); Feb 2022 |
| 2023 | NINDS HEAL U19, ZNS1 SRB-R (11); Feb 2023. |
| 2023 | Drug Discovery and Molecular Pharmacology B Study Section (DMPB), Feb 2023 |
| 2023 | UG3/UH3 NINDS/HEAL special emphasis panel ZNS1SRB-V (03); June 2023 |
| 2023 | NCI/NIH ZCA1 TCRB-J (J2); SEP-8: NCI Clinical and Translational Cancer Research |
| 2023 | NINDS Special Emphasis Panel, ZNS1 SRB-R (18), U19; Feb 2024. |

**C. Journal Reviewer (selected list)**

1) Chemical Biology and Drug Design
2) Expert Opinion on Therapeutic Patents
3) Bio-organic Medicinal Chemistry
4) Chem Bio Chem (Wiley VCH-de)
5) Recent Patents on CNS Drug Discovery
6) Life Sciences
7) Journal of Pharmacology and Experimental Therapeutics (JPET)
8) Neuropsychopharamcology, Nature Publishing Group (NGP)
9) Bio-organic Medicinal Chemistry Letters
10) Drugs of the Future
11) Journal of Medicinal Chemistry
12) Journal of Organic Chemistry
13) ACS Chemical Neuroscience
14) Frontiers in Pharmacology, section Translational Pharmacology

**D. MEMBERSHIP PROFESSIONAL SOCIETIES**

1999- current Association of Carbohydrate Chemists and Technologists
2000- current American Chemical Society
2003- current International Cannabinoid Research Society (ICRS)
2008- current Member of NIDA Networking Project (NNP)
2010- current Member of American Association of Pharmaceutical Scientists (AAPS)
2011- current Member of Rho Chi Honor Society
2015- 2017 Member of Society of Neuroscience

## MAJOR TEACHING EXPERIENCE

2006-2010: Assistant Research Professor (CDD; Northeastern University)
2010-2021: Assistant/Associate Professor (Northeastern University)
2021-present: Professor (Northeastern University)

**Graduate Courses**
2011-*2020* : Drug Discovery Journal Club (PHSC6300-003; Fall semester)- Course Coordinator
2011 : Chemistry and Biology of Drugs of Abuse (PHSC6222; Fall semester)
2013- *Present* : Pharmacokinetics and Drug Metabolism (PMST6252; Spring semester)
2016- *2019* : Principles of Drug Design (PHSC5400; Fall semester);

**Undergraduate Courses**

2006-2020 : Pharmacology and Medicinal Chemistry I (PHSC4501); Principal instructor for teaching medicinal chemistry
2007-2021 : Pharmacology and Medicinal Chemistry II (PHSC4502); Course coordinator and Principal instructor for teaching medicinal chemistry (Course Coordinator)
2014-Present : Anti-infective Agents (PHSC5360)

**RESEARCH MENTORING:** (* indicate students for whom my role is mentor as well as advisor)

***UNDERGRADUATE MENTORING:***

| # | Year | Student's name | Degree | Current Position |
|---|---|---|---|---|
| 1 | 08/2011-12/2011 | Shivan Acharya | Pharm.D. | Clinical Pharmacist, CA. |
| 2. | 01/2012-04/2012 | Monica Taing | Pharm. D | Medical Science Liaison, 4Front |
| 3. | 02/2014- 09/2014 | Olatokunbo Onabanjo | Pharm. D. | Graduated from NEU |
| 4. | 02/2014- 08/2014 | Lucia Zhu | Pharm. D. | Graduate from NEU |
| 5. | 09/2018- 04/2019 | Ethan Rawl | Pharm. D. | Current Student at NEU (P4) |
| 6. | 09/2016 – 12/2017 | Angela Sung | Pharm. D. | PGY-1 Pharmacy Resident |
| 7. | 10/2019- 02/2020 | Mark DiFulvio | Pharm.D. | Student at NEU (P1) |
| 8. | 09/2021- current | Tavesh Gadkari | B.S. Pharm Sci | Third year student at NEU |
| 9. | 08/2022- current | Andrew Wohlbruck | B.S. Pharm Sci | Third year student at NEU |
| 10. | 08/2022- current | Aisha Bailey | B.S. Pharm Sci | Third year student at NEU |
| 11. | 08/2023- current | James Saskowsky | B.S. Pharm Sci | Second year student at NEU |

**PH.D./M.S. THESIS MENTORING:**

| | | | | |
|---|---|---|---|---|
| 1. | 1999-2001 | Alok Singh* | M.S. Med. Chem. | Novartis (NIBR), MA. |
| 2. | 2003-2006 | Jin Zhang* | M.S. Med. Chem. | Harvard Medical School, MA. |
| 3. | 01/2007-08/2007 | Vince Abeyta$^{+}$* | M.S. Med. Chem. | Boehringer Ingelheim, CT. |
| 4. | 2007-2011 | Heidi Teng* | Ph.D. Med. Chem. | Aldrich, MA. |
| 5. | 2010-09/2011 | Abhijit Kulkarni | M.S. Med. Chem. | Eli Lilly, Philadelphia |
| 6. | 09/2011-04/2012 | Khushbu Shah | M.S. Med. Chem. | Scientific Advisor at Kramer Levin |
| 7. | 09/2012-09/2014 | Prisca Mungalachetty | M.S. Med Chem. | Novartis (NIBR), Boston |
| 8. | 09/2011-12/2012 | Ameya Ranade | M.S. Med. Chem. | Pursuing Ph.D. in Canada |
| 9. | 10/2011-11/2013 | Vasantha Duggirla | M.S. Med Chem. | |
| 10. | 2007-06/2012 | Marsh D'Souza* | Ph.D. Med. Chem. | Post-doc at Scripps |
| 11. | 2006-06/2012 | Rishi Sharma* | Ph.D. Med. Chem. | Scientist at MicroConstants Inc. |
| 12. | 2007-08/2012 | Shama Bajaj* | Ph.D. Med. Chem. | MIT, Cambridge, MA. |
| 13. | 10/2008-10/2012 | Ritesh Tichkule** | Ph.D. Med Chem. | Novartis (NIBR), Boston. |
| 14. | 09/2011-08/2016 | Abhijit Kulkarni | Ph.D. Med. Chem. | Eli Lilly, Philadelphia |

| | | | | |
|---|---|---|---|---|
| 15. | 02/2014-08/2015 | Siddhi Honavar | M.S. Med. Chem. | GSK, Philadelphia |
| 16. | 09/2014-08/2016 | Sharvik Shirodkar | M.S. Med Chem. | Kaleido Biosciences, Inc. |
| 17. | 09/2014-08/2016 | Ninad Dixit | M.S. Med Chem. | Radikal Therapeutics Inc. |
| 18. | 09/2016-05/2022 | Peter Schaffer | M.S. Med Chem. | Looking for a job in pharma. |
| 19. | 09/2017-05/2022 | Lucas Cantwell | M.S. Med Chem | Pliant Therapeutics, San Fransico,. |
| 20. | 09/2018- 08/2019 | Sahil Seth | M.S. Med Chem | Takeda, Cambridge, MA. |
| 21. | 09/2018 – 05/2020 | Wilder Felix | M.S. Med Chem (Thesis) | |
| 22. | 09/2020-currrent | Wilder Felix | Current Ph.D. student | |
| 23. | 09/2021- current | Harvens Beauzile | Current Ph.D. student | |
| 24. | 09/2023- current | Sahil Seth | Current Ph.D. student | |

---

* indicates my role as co-advisor; + indicates my role as mentor

**POST-DOCTORAL FELLOW MENTORING:**

| | | | | |
|---|---|---|---|---|
| 1. | 2005-2008 | Dr. Vidyanand Shukla* | --- | Millipore Sigma, Natick, MA. |
| 2. | 2007-2009 | Dr. Shaine Cararas* | --- | Researcher, Louisiana |
| 3. | 02/2011-08/2015 | Dr. Pushkar Kulkarni | --- | Barnett Institute/Department of |
| | | (Davis Foundation Fellowship) | | Pharm. Sci. NEU |
| 4. | 10/2013-09/2014 | Dr. Ganesh Chaturbhuj | --- | Professor, Institute of Chemical |
| | | (Indo-US project; Raman Fellowship) | | Technology (ICT), Mumbai, India. |
| 5. | 05/2015-04/2016 | Dr. Gopalkrushna Waghule | | Zydus Pharma, India |
| 6. | 09/2016-08/2017 | Dr. Abhijit Kulkarni | | Eli Lilly, Philadelphia. |
| 7. | 01/2015-12/2022 | Dr. Sumanta Garai | | Scientist II, Carmot Therapeutics, |
| | | (Senior Research Scientist) | | Berkley, CA. |
| 8. | 08/2022- present | Dr. Hina Andleeb | | Current Research Scientist, NU. |
| 9. | 02/2022- present | Dr. Pradip Gadekar | | Current Research Scientist, NU. |

**GRADUATE STUDENT THESIS COMMITTEE**

| | | |
|---|---|---|
| 1. | 2007-2012 | Shama Bajaj, (Ph.D.; Medicinal Chemistry) |
| 2. | 2007-2012 | Ritesh Tichkule, (Ph.D.; Medicinal Chemistry) |
| 3. | 2011- 2013 | Namita Dodwadkar, (Ph.D.; Pharmaceutics) |
| 4. | 2011-2013 | Vasantha Duggirala, (M.S.; Medicinal Chemistry) |
| 5. | 2011-2013 | Ameya Ranade, (M.S.; Medicinal Chemistry) |
| 6. | 2012-2014 | Madhura Deshpande, (Ph.D.; Pharmaceutics) |
| 7. | 2012-2014 | Prisca Mungalachetty, (M.S.; Medicinal Chemistry) |

| | | |
|---|---|---|
| 8. | 2013-2015 | Siddhi Honavar, (M.S.; Medicinal Chemistry) |
| 9. | 2012-2017 | Pranali Deshpande, (Ph.D.; Pharmaceutics) |
| 10. | 2011- 2016 | Abhijit Kulkarni, (Ph.D.; Medicinal Chemistry) |
| 11. | 2014- 2016 | Ninad Dixit, (M.S.; Medicinal Chemistry) |
| 12. | 2014- 2016 | Sharvik Shirodkar (M.S.; Medicinal Chemistry) |
| 13. | 2012- 2017 | Aditi Jhaveri (M.S.; Pharmaceutics) |
| 14. | 2016- 2020 | Prisca Mungalachetty (Ph.D.; Bioanalytical Chemistry). |
| 15. | 2016-2018 | Krishnamohan Raja (M.S.; Medicinal Chemistry) |
| 16. | 2017-2019 | Sahil Seth (M.S.; Medicinal Chemistry) |
| 17. | 2015-2021 | Peter Schaffer, (Ph.D.; Medicinal Chemistry) |
| 18. | 2016-2021 | Lucas Cantwell, (Ph.D.; Medicinal Chemistry) |
| 19. | 2018-2020 | Wilder Felix, (M.S.; Medicinal Chemistry) |
| 20. | 2015-2020 | Jiayi Pan, (Ph.D.; Pharmaceutics) |

**INVITED TALKS:**

1. "*Endocannabinoid System as an Emerging Therapeutic Target*" given at Institute of Chemical Technology (ICT, formerly UDCT), Matunga, Mumbai (2011). This lecture was sponsored by Department of Pharmaceutical Sciences and Technology, UGC-Center for Advance Studies, India.
2. "*Cannabinoid Receptors as Therapeutic Targets*" given at Bombay College of Pharmacy (BCP), Mumbai, India (2011).
3. "*Targeting Obesity with Negative Allosteric Modulators of CB1 Cannabinoid Receptor*" in Discovery of Target meeting, (2012).
4. "*Tuning the Endocannabinoid System: Alllosteric Modulators of CB1 Cannabinoid Receptor*" given in the department of Pharmaceutical Sciences, St. John University, (2013).
5. "*Allosteric Modulators of CB1 Cannabinoid Receptor*" given in the department of pharmacology and therapeutics, University of Florida, (2013).
6. "*Tuning Endocannabinoid System for Therapeutic Gain*" given at ICT, India, on 28$^{th}$ March 2014.
7. "*Novel Therapeutic Opportunities via Allosteric Modulation of CB1 Cannabinoid Receptor*" given at Indian Institute of Science Education and Research (IISER), Pune, India, (2014).
8. "*Tuning the Endocannabinoid System: Allosteric Modulators of CB1 Cannabinoid Receptor*" given at Indian Institute of Technology (IIT), Bombay, India, (2014).
9. "*Novel Therapeutic Opportunities via Allosteric Modulation of CB1 Cannabinoid Receptor"* given at McLean Hospital, Harvard Medical School, Belmont, MA, (2014).
10. "Tuning the Endocannabinoid System: Allosteric Modulators of CB1 Cannabinoid Receptors" given at School of Medicine, Dept. of Neuroscience, University of New Mexico, Albuquerque, NM, (2014).
11. "*Tuning the Endocannabinoid System: Allosteric Modulators of CB1 Cannabinoid Receptors*" given at Dept. of Chemistry and Biochemistry, UMASS Dartmouth, MA, (2014).

12. "*Tuning the Endocannabinoid System: Allosteric Modulators of CB1 Cannabinoid Receptors*" given at the *Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences (EACPHS), Wayne State University, Detroit, MI*, (2014).
13. "*Safer Medications through Allosteric Modulation of CB1 Cannabinoid Receptor*" given at the Dept. of Pharmaceutical Sciences, Duquesne University, Pittsburg, PA, (2014).
14. "*Safer Medications through Allosteric Modulation of CB1 Cannabinoid Receptor*" given at the Dept. of Pharmacology and Molecular Sciences, John Hopkins School of Medicine, Baltimore, MD, (2014).
15. "*Safer Medications through Allosteric Modulation of CB1 Cannabinoid Receptor*" given at the Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN, (2014).
16. "*Safer Medications through Allosteric Modulation of CB1 Cannabinoid Receptor*" given at 2nd International Congress of Society for Ethnopharmacology, Nagpur, India, (2015).
17. "*Safer Medications through Allosteric Modulation of CB1 Cannabinoid Receptor*" given at National Chemical Laboratory, NCL, Pune, (2015).
18. "Therapeutic Potential of CB1 Allosteric Modulators" given at Nagpur University, India, September 2017.
19. "Positive Allosteric Modulation of CB1 Cannabinoid Receptor as a Promising Therapeutic Strategy for Treating Pain, Glaucoma and Neurodegenerative Disorders" given at Temple University, Philadelphia, May 2018.
20. "*Allosteric Modulation of CB1 Cannabinoid Receptor*" given at IISER, Pune, India (2019).
21. "CB1 Positive Allosteric Modulators for Treating Anxiety Disorders" Society of Biological Psychiatry, 74th Annual Meeting, May 16-18, 2019, Chicago, IL.
22. Invited speaker at: 8th International symposium on Current Trends in Drug Discovery Research: Ageing Associated Metabolic & CNS Disorders, 12 - 14 March, 2022. CSIR-Central Drug Research Institute, Lucknow